text:
Thank you for visiting our web site. Please click on the links below to download more information about our company, services and research.
RTI Health Solutions Overview Brochure
CNS and Neurology
Diagnostics and Medical Device
Infectious Disease
Mental Health
Health Economics
Decision-Analytic Modeling
Database Research
Multinational Chart Reviews
Innovative Data Analysis for Demonstrating Product Value
Multi-Criteria Decision Analysis
Health-State Utilities: Strategy and Assessment
Capturing the Patient's Perspective
Market Access
Payer and Pricing Research
Global Value Dossiers
AMNOG Submissions
NICE Submissions
Health Preference Assessment
Epidemiology: Database Research
Epidemiology Literature Reviews
Therapeutic Risk Management
REMS/Risk Minimization Surveys
Surveys and Observational Studies
Outcomes Research Data Analysis
Oncology Data Analytics
Driving Drug Development at Every Step
Andrews, E., D. DiBenedetti, B.H. Forsyth, A. Gilsenan, K. Hollis, S. Lewis, M. Price, P. Tennis, and L. Zografos. (Nov 2012). Risk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Assess Goals Related to Knowledge [White Paper].
Johnson, F.R.. (September 2011). Combining Revealed and Stated Preferences to Predict Uptake and Adherence [White Paper].
Johnson, F.R., and A.B. Hauber. (June 2008). Quantifying Patient Benefit-Risk Tradeoff Preferences: A Brief Introduction [White Paper].
Johnson, F.R.. (2004 Sept). When QALYs Don't Work: Measuring and Using General Time Equivalents [White Paper].
Perez-Gutthann, S.. Post-Approval Safety Studies: Impact of 2012 PV Legislation & Guidance.
Gilsenan, A., D.H. Harris, K. Midkiff, E. Andrews, N. Kellier, and D. Masica. Approaches to Long-Term Surveillance for Rare Cancer Events.
Varas-Lorenzo, C., N. Riera-Guardia, B. Calingaert, A. Margulis, M. Pladevall, G. Miguel, S. Romio, M. Sturkenboom, and S. Perez-Gutthann. Cardiovascular Risk With Glitazones and Metformin: Results From a Systematic Review of Observational Studies.
Johannes, C., L. McQuay, P. Tennis, C.A. Camargo, M. Schatz, K. Midkiff, S. Lanes, R. DiSantostefano, and K. Davis. Characteristics of Initiators of Asthma Maintenance Medications in 10 Health Care Populations.
Harris, D.H., K. Midkiff, A. Gilsenan, N. Kellier, D. Masica, and E. Andrews. Eight-Year Results From the US Osteosarcoma Surveillance Study.
Pladevall, M., L. Zografos, I. Tatt, P. Napalkov, E. Andrews, and S. Perez-Gutthann. Feasibility Evaluation for a Rituximab Utilization Study to be Conducted in Infusion Centers.
Midkiff, K., C. Johannes, P. Tennis, B. Calingaert, L. McQuay, D.H. Harris, and E. Andrews. Identifying Causes of Death in a Large Cohort of Asthma Patients.
Riera-Guardia, N., A. Margulis, M. Pladevall, C. Varas-Lorenzo, and S. Perez-Gutthann. Methodological Issues in Observational Studies of the Cardiovascular Risk Associated With Glucose-Lowering Medications: Results of a Systematic Review and Evaluation.
Margulis, A., M. Pladevall, N. Riera-Guardia, C. Varas-Lorenzo, L. Hazell, and S. Perez-Gutthann. Quality Assessment of Observational Studies in a Drug-Safety Systematic Review—Comparison of Two Tools, the Newcastle-Ottawa Scale and the RTI Item Bank.
Varas-Lorenzo, C., N. Riera-Guardia, J. Castellsague, A. Arfe, and S. Perez-Gutthann. The SOS Project: Risk of Heart Failure and Use of NSAIDs–A Meta-Analysis of Epidemiological Studies.
Woods, M.S., S. Kiri, C.S. Ling, L. McCrink, E. Zimovetz, and B. Hass. A Systematic Review of Economic Evidence in Hepatitis C: an Overview of Cost, Utility, and Cost-effectiveness Data.
Woods, M.S., S. Kiri, C.S. Ling, L. McCrink, E. Zimovetz, and B. Hass. A Systematic Review of Economic Evidence in Hepatitis C: Methods Used in Recent Economic Evaluations.
Brennan, V.K., S. Dixon, G. Jones, S. Radley, R. Jacques, H. Wood, and W. Ledger. An Economic Evaluation Alongside a Clinical Trial in Pelvic Floor Medicine.
Stull, D., D.W. McBride, A. Gnanasakthy, and M. Balp. Correlations Between Changes In The Urticaria Activity Score (UAS7) And The Dermatology Life Quality Index (DLQI) From Baseline To 28 Or 40 Weeks: Comparisons Of Trajectories Of Change In Patients With Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU).
Wolowacz, S.E., J.A. Brockbank, A. Gonschior, and T. Sunderland. Cost-effectiveness of Dabigatran Etexilate for the Secondary Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism in the UK.
Mauskopf, J., D. McBride, U. Mallya, and S.R. Feldman. Developing Realistic Pathways in Cost-effectiveness Models of Psoriasis: What to Do When a Biologic Fails.
Hogue, S., K. Hollis, L. McLeod, A.P. Brogan, and A. Heyes. European Payer Advisors' Use of Observational Studies for Health Care Reimbursement Decisions.
Schaller, S., J. Mauskopf, C. Kriza, P. Wahlster, and P. Kolominsky-Rabas. Methodological Challenges of Cost-of-Illness Studies in Dementia: A Systematic Review.
Mohamed, A., Y. Qian, B. Hauber, H. Collins, G. Hechmati, F. Gatta, and J. Arellano. Nurses' Preferences for Bone Metastases Treatments in the United States.
Gonzalez, J.M., F.R. Johnson, A.O. Fairchild, T. Irony, and M. Ho. Patients at the Center of Regulatory Decisions: Using Stated-Preference Data to Help Regulators Answer Difficult Questions.
Qian, Y., A. Mohamed, B. Hauber, H. Collins, G. Hechmati, F. Gatta, and J. Arellano. Patients' and Caregivers' Preferences for Bone Metastases Treatments in the United States.
Qian, Y., G. Hechmati, A. Mohamed, B. Hauber, J. Arellano, F. Gatta, I. Haynes, and A. Bahl. Physicians' Preferences for Bone Metastases Treatments in France, Germany, and the United Kingdom.
Arellano, J., A. Mohamed, B. Hauber, H. Collins, G. Hechmati, F. Gatta, and Y. Qian. Physicians' Preferences for Bone Metastases Treatments in the United States.
Hogue, S., A.P. Brogan, and A. Heyes. Point Of Care Tests: The Long and Winding Road to Reimbursement.
Davis, K., and S. Candrilli. Recent Trends in Hospital Costs, Length of Stay, and Mortality Associated With Pediatric Meningococcal Disease in the United States.
Davis, K., and S. Candrilli. Recent Trends in Incidence and Demographics of Pediatric Meningococcal Disease in the United States.
von Scheele, B., J. Mauskopf, T. Brodtkorb, C. Ainsworth, C. Galani Berardo, and A. Patel. Relationship Between Modelling Approaches and Reported Outcomes: Case Studies of Models for the Treatment of Schizophrenia.
Rycroft, C., M. Fernandez, and K. Copley-Merriman. Systematic Literature Reviews at the Heart of Health Technology Assessment:a Comparison Across Markets.
Ling, C.S., U. Weisgerber-Kriegl, A.I. Njue, A. Heyes, and J. Kaye. The Effect of Positive Margins on Outcomes in Breast Cancer.
Ainsworth, C., S. Kiri, C.S. Ling, A.E. Heyes, and B. Hass. The Global Burden, Incidence, and Prevalence of Chronic Hepatitis C.
Cawson, M., C. Knight, M. Hirst, and M. Dunlop. The Potential of a Reduction in the Risk of Opioid-Related Fractures to Drive the Cost-effectiveness of an Analgesic.
Gonzalez, J.M., F.R. Johnson, and F. Mughal. UK Psoriasis Patients' Tolerance for Therapeutic Risks in Return for Symptom Improvement.
Raspa, M., E. Bishop, S. Candrilli, D. Mitra, P. Sacco, J. Petrillo, and D. Bailey. US Caregiver Burden in Fragile X Syndrome as a Function of a Health-State Utility Index.
Odom, D., A.J. Brogan, S.E. Talbird, and B. Schenkel. A Meta-Analysis of Randomized, Controlled Trials of Ustekinumab and Adalimumab for Moderate-to-Severe Psoriasis.
Herring, W., D. Mladsi, L. Miles, and N. Ronquest. A Novel Approach to Ranking Parameter Uncertainty in One-Way Sensitivity Analysis: What Tornado Diagrams Are Missing.
Davis, K.L., T. Fitzgerald, A. Kulkarni, J. Meyers, P. Svarvar, and D. Hewitt. Comparative Risk of Adverse Treatment Effects in Parkinson's Disease: Evidence From a Large Employer Population.
Yang, H., J. Mauskopf, and E. Dasbach. Comparing Vaccine Effectiveness Estimates in Cost-effectiveness Analyses of Pneumococcal Vaccination in Adults.
Davis, K.L., T. Fitzgerald, J. Meyers, A. Kulkarni, P. Svarvar, and D. Hewitt. Economic Burden of Adverse Treatment Effects in Parkinson's Disease: Evidence From a Large Employer Population.
Davis, K., J. Meyers, Z. Zhao, P. McCollam, and M. Murakami. High-Risk Vascular Disease in Japan: Evidence on Incidence and Prevalence, Patient Characteristics, and Treatment Rates From a Large Japanese Claims Database.
Davis, K., T. Fitzgerald, J. Meyers, A. Kulkarni, P. Svarvar, and D. Hewitt. Incidence of Adverse Treatment Effects in Parkinson's Disease: Evidence From a Large Employer Population.
Herring, W.L., D. Mladsi, and J. Mauskopf. Patient-Level Simulation Modeling for Economic Evaluations: Opportunities and Challenges in a Practical Setting.
Hogue, S., A. Scott, D. van Amerongen, K. Hollis, L. McLeod, and A. Brogan. Payer and Decision Maker Use of Observational Studies for Health Care Reimbursement Decisions.
Candrilli, S., and S. Karve. Recent Trends in Type 2 Diabetes Mellitus–Related Inpatient Care Among Pediatric Patients in the United States.
DiBenedetti, D., T. Coles, and T. Sharma. Recruiting Patients With a Rare Blood Disorder and Their Caregivers Through Social Media.
Mordin, M., S. Hogue, S. Barrows, and D. van Amerongen. Safe and Effective Versus Reasonable and Necessary: Is the Deck Stacked Against Medical Devices?.
Mohamed, A., F. Johnson, J. Gonzalez, and M.M. Balp. Stated Time-Allocation, Adherence, and Health-Outcome Trade-off Preferences in Cystic Fibrosis Households.
Barrett, A., D. DiBenedetti, H. Phatak, and U. lloeje. Structured Review of Patient-Reported Outcome Instruments for Assessing Atrial Fibrillation.
Mordin, M., C. Copley-Merriman, J. Mauskopf, C. Sweeney, S. Bhattacharyya, C. Farup, W. Beach, L. Higgins, and L. McIntyre. Surgical Innovation: Do We Need a More Balanced Framework for Evidence?.
Brennan, V.K., A.D. Colosia, C. Copley-Merriman, B. Hass, and R. Palencia. Systematic Literature Review of Costs Related to Patients With Type 2 Diabetes Mellitus Experiencing a Stroke or Myocardial Infarction.
Brennan, V.K., A.D. Colosia, C. Copley-Merriman, B. Hass, and R. Palencia. Systematic Literature Review of Utilities Related to Patients With Type 2 Diabetes Mellitus Experiencing a Stroke or Myocardial Infarction.
Ronquest, N., D. Mladsi, C. Hopley, and E. Edgell. The Economic Value of an Innovative Knee Implant System for Total Knee Arthroplasty.
Copley-Merriman, K., B. Olanrewaju, and S. Hogue. The Temporal Relationship Between NSAIDs and Risk of Gastrointestinal, Cardiovascular, and Renal Events: A Systematic Review.
DiBenedetti, D., T. Coles, C.S. Ling, T. Sharma, and L. Pericleous. Web-Based Study of Patients and Caregivers in the United States and Canada: Perspectives on Improvements in Stability of Factor VIII Products for Hemophilia A.
Willke, R., F.R. Johnson, and U. Persson. Willingness to Pay, Ability to Pay, and Money-Equivalent Benefit: Measuring And Using Monetized Health Benefits.
Karve, S., D. Mitra, K.V. Rajagopalan, D. Blum, T. Grinnell, and V. Bollu. Impact of concomitant use of antiepileptic drugs and statins on risk of cardiovascular events.
Bollu, V., S. Karve, and D. Mitra. Prevalence of baseline hyponatremia and association with initial antiepilepsy treatment selection among epilepsy patients.
Markowitz, M., S. Karve, D. Fu, J. Lindenmayer, C. Wang, S. Candrilli, and L. Alphs. Assessing Medication Adherence and Health Care Utilization and Cost Patterns Among Hospital Discharged Patients With Schizoaffective Disorder.
Riera-Guardia, N., C. Saltus, C. Bui, D.H. Harris, J.A. Kaye, P. Tennis, J. Castellsague, and S. Perez-Gutthann. Back in Barcelona: The Landscape of Database Research Over the Last Decade.
Zografos, L.. Considerations for Implementing Surveys Evaluating Effectiveness: Sample Recruitment, Ethics, and Privacy.
Zhou, X., B. Sherrill, Y. Wu, L. Bennett, and J. Wang. Evaluating Effects of Changing Treatments in Longitudinal Studies.
Gilsenan, A.W., N. Kellier, D.H. Harris, E.B. Andrews, and D.N. Masica. Linking a Voluntary Patient Registry With US State Cancer Registries for Possible Signal Detection.
Andrews, E.B.. Methodological Considerations for Surveys Evaluating RMM Effectiveness: Design and Analytic Strategies to Minimize Bias.
Perez-Gutthann, S.. New PV Legislation: A Call to Arms to the Pharmacoepidemiology Community. Post-Approval Safety Studies.
Kaye, J.A., J. Castellsague, C. Bui, B. Calingaert, L.J. Mcquay, N. Riera-Guardia, C. Saltus, S. Quinlan, C.N. Holick, P.M. Wahl, K. Suzart, K.J. Rothman, M.A. Wallander, and S. Perez-Gutthann. Risk of Acute Liver Injury in a Cohort of Oral Antimicrobial Users.
Midkiff, K., B. Calingaert, P. Tennis, D.H. Harris, and E.B. Andrews. Using an Automated Computer-Based Algorithm to Increase the Efficiency of Selecting the Best Match From National Death Index Linkage Results.
Helbert, M., F. Pang, M. Alvarez-Reyes, I.V. Pearson, S. Wolowacz, and L. Diwakar. A Cost-Effectiveness Comparison of Icatibant and C1-Esterase Inhibitor Concentrate for the Symptomatic Treatment of Acute Attacks of Types I and II Hereditary Angioedema in the UK Setting.
Pearson, I.V., S.E. Wolowacz, A.H. Irving, J.A. Brockbank, B. Chubb, J. Gundgaard, A. Briggs, and M. Davies. A Systematic Review of Recent Data Describing the Risk of Complications in Type 1 Diabetes Mellitus Patients.
McBride, D.W., A. Kilburg, and J. Mauskopf. An Early Assessment of the German Federal Joint Commission Resolutions of Additional Clinical Benefit.
Helbert, M., F. Pang, M. Alvarez-Reyes, N. Roskell, and L. Diwakar. An Indirect Comparison of Icatibant and Four Other Therapies for the Symptomatic Treatment of Acute Attacks of Hereditary Angioedema Types I and II.
Hicks, K., S. Earnshaw, C. McDade, J.W. Shaw, and M.A. Cifaldi. Benefit-risk Analysis of Adalimumab and Alternative Treatments for Moderate to Severe Rheumatoid Arthritis.
Okumura, K., H. Inoue, M. Yasaka, J. Gonzalez, B. Hauber, K. Iwamoto, E. Wang, B. Rossi, and J. Briere. CHARACTERISTICS INFLUENCING JAPANESE ATRIAL FIBRILLATION PATIENTS' PREFERENCES FOR ANTICOAGULANTS USE.
Candrilli, S., K. Davis, and L. Yen. Characteristics of Diverticulitis-Related Emergency Department Visits in the United States.
Davis, K., D. Mitra, and L. Yen. Clinical Characteristics, Treatment Patterns, and Resource Utilization in a Real-World European Population With Diverticulitis.
Gnanasakthy, A., L. Doward, M. Clark, M. Mordin, and C. DeMuro. Concordance of PRO Labeling Claims Between the FDA and EMA.
Williams, P., J. Mauskopf, A. Kilburg, and J. Lebiecki. Estimating the Probability of a Favorable Assessment of Additional Clinical Benefits for a New Drug in Germany Using an MCDA Approach.
Williams, P., J. Mauskopf, A. Kilburg, and J. Lebiecki. Estimating the Probability of a Positive Recommendation for Reimbursement for a New Drug in the UK Using an MCDA Approach.
Mauskopf, J., W. Beach, L. McIntyre, S. Bhattacharyya, L. Higgins, M. Mordin, and K. Copley-Merriman. Evidence-Based Medicine: A Case Study of Its Application to Innovative Surgical Procedures in the United Kingdom.
Broekhuizen, H., K. Groothuis, B. Hauber, and M. IJzerman. Integrating patient preferences and clinical trial data in a Bayesian model for quantitative benefit-risk assessment.
Okumura, K., H. Inoue, M. Yasaka, J.M. Gonzalez, A.B. Hauber, K. Iwamoto, E. Wang, B. Rossi, and J. Briere. JAPANESE PATIENTS' AND PHYSICIANS' PREFERENCES FOR ANTICOAGULANTS USE IN ATRIAL FIBRILLATION - RESULTS FROM A CONJOINT-ANALYSIS STUDY.
Mordin, M., M. Clark, L. Doward, and M. Willian. Pediatric Patient-Reported Outcomes Assessment:A Case Study in Epidermolysis Bullosa.
Colosia, A.D., R. Palencia, and S. Khan. Prevalence of Hypertension and/or Obesity in Patients With Type 2 Diabetes Mellitus Throughout the World: A Systematic Literature Review.
Mauskopf, J., and S. Lee. Rates of Influenza Complications by High-Risk Group.
Roskell, N., J. Setyawan, E. Zimovetz, and P. Hodgkins. Systematic review and network meta-analysis of treatments used for Attention Deficit Hyperactivity Disorder (ADHD).
Woods, M., E. Zimovetz, D. McBride, S. Beard, and M. Balp. Systematic Review of Economic Evaluations, Utility Estimates, Resource Utilisation, and Costs in Chronic Idiopathic Urticaria.
Zimovetz, E., J. Setyawan, S. Beard, and P. Hodgkins. Systematic review of health-state utilities in Attention Deficit Hyperactivity Disorder (ADHD).
Mohamed, A., J. Zhang, F.R. Johnson, I. Lomon, E. Malvolti, R. Townsend, C. Östgren, and K. Parhofer. The Avoidance of Weight Gain is Important for Oral Type 2 Diabetes Treatments in Sweden and Germany: A Patient Preference Study.
Mitra, D., J. Whiteley, S. Iyer, S. Candrilli, and J. Kaye. Treatment and Response Patterns in Chronic Myeloid Leukemia: Evidence From a Retrospective Study in Canada, Australia, and South Korea.
Brennan, V.K., and S. Dixon. A Literature Review for Empirical Studies of Process Utility.
Lewis, S., M. Price, M. Mordin, K. Dwyer, R. Heekin, P. Yates, S. O'Brien, and D. Beverland. Assessing Performance Following Primary Total Knee Arthroplasty: Development of the Patient's Knee Implant Performance (PKIP) Measure.
Brown, T.M., B. Olanrewaju, L. Deal, E.C. Katz, C. Chiou, S. Martin, and S. Fehnel. Assessing Pruritus Among Patients With Atopic Dermatitis: Targeted Literature and Instrument Review.
Karve, S., and S. Candrilli. Association Between Emotional Support and Current Health Status Among US Adults With Cardiovascular Disorders.
Mladsi, D., W.L. Herring, and S. Earnshaw. Cost-effectiveness Analysis in Personalized Medicine: General Hypotheses and Corresponding Decision Tree Structures for Screening, Diagnostic, Predictive, Prognostic, Surveillance, and Monitoring Tests.
Yang, J., and F. Johnson. Fictitious Preferences or Felicitous Recoding? Conjoint Respondents Who Make Sense of Nonsensical Questions.
Mauskopf, J.. Incidence-Based Versus Prevalence-Based Economic Evaluations for the Assessment of New Health Care Interventions.
Mohamed, A., J. Yang, A.B. Hauber, Z. Liu, M. Wong, J. Rogerio, and C. Garay. Patient Benefit-Risk Preferences for Advanced Renal Cell Carcinoma Treatments: Results From a Conjoint Analysis Study.
Meyers, J., Y. Yu, and K. Davis. Patient Survival, Health Care Utilization, and Costs in Medicare Patients With Acute Myeloid Leukemia Compared With Matched Controls.
Poulos, C., A.B. Hauber, J.M. Gonzalez, S. Ogale, and A. Turpcu. Patient Tradeoffs Between Frequency and Duration of Biologic Treatments for Rheumatoid Arthritis.
Davis, K.L., L. Yen, E. Loftus, and P. Hodgkins. Pre-to-Postdiagnosis Increase in Utilization and Costs of Chronic-Use Medications and Other Medical Resources in Managed Care Enrollees With Diverticulitis.
Mohamed, A., V. Kilambi , M. Luo, and J. Li-Mcleod. Preferences for Immunoglobulin Treatment Administration Attributes by Patients and Parents.
Gonzalez, J.M., B. Hauber, B. Levitan, and P. Coplan. Structured Benefit-Risk Assessment of Triptan Treatment Using Patient-Preference Data.
Yen, L., K.L. Davis, and S. Candrilli. The Direct Economic Burden of Diverticulitis Recurrence Among Managed Care Enrollees.
Mladsi, D.M., J.B. Graham, and N.A. Ronquest. Trade-off Analysis: An Extension of Threshold Pricing Analysis.
Talbird, S., J. Thompson, J. Mauskopf, A. Brogan, and B. Standaert. Translating Outcomes from a Dynamic Transmission Model for Vaccination to Cost-Effectiveness Estimates: The Impact of Different Analytic Approaches on the Results.
Roskell, N., E. Mendelson, D. Whalley, and C.J. Knight. Using a Condition-Specific Measure of Patient-Reported Outcomes to Derive Utilities in Myelofibrosis.
Panish, J., S. Karve, S. Candrilli, and R. Dirani. Association Between Adherence and Persistence with Antipsychotics and Outcomes Among Medicaid Patients with Schizophrenia.
Brogan, A.J., J.D. Miller, S.E. Talbird, J. Thompson, and B. Deniz. Long-term Clinical Value of Telaprevir for Treatment of Treatment-naïve and Treatment-experienced Patients with Hepatitis C Virus Infection: Projections Using Decision-analytic Modeling.
Chirila, C., T.M. Gilligan, A. Gilsenan, M. Price, K. Hollis, B. Calingaert, L. Zografos, and E. Andrews. A Comparison of Factors Influencing Patient Knowledge: Results Across Selected REMS Surveys.
Midkiff, K., D.H. Harris, A. Gilsenan, Y. Wu, and E. Andrews. Drug Safety Studies Using Cancer Registry Data: Confluence of Elements Impacting the Interview Response Rate.
Gilsenan, A., K. Hollis, L. Zografos, B. Calingaert, and E. Andrews. Examination of Respondent Bias and Patient Characteristics in Multiple REMS Assessment Surveys.
Johannes, C., E. Andrews, L. McQuay, M. Frohlich, and R. Sims. Incidence of Cerebrovascular Accidents in Men With Prostate Cancer.
Gilsenan, A., D.H. Harris, K. Midkiff, J. Wright, and E. Andrews. Linking With Multiple State Cancer Registries for Safety Surveillance Study – Is it Feasible?.
Hollis, K., B. Calingaert, T.M. Gilligan, C. Sweeney, M. Price, S. Perez-Gutthann, and E. Andrews. Quinolones REMS Evaluation Surveys.
Castellsague, J., F. Pisa, V. Rosolen, N. Riera-Guardia, M. Giangreco, E. Clagnan, F. Tosolini, L. Zanier, F. Barbone, and S. Perez-Gutthann. Use of Nimesulide, Other NSAIDs, and the Risk of Upper Gastrointestinal Complications in Friuli Venezia Giulia, Italy.
Pisa, F., D. Drigo, N. Riera-Guardia, J. Castellsague, V. Rosolen, E. Clagnan, F. Tosolini, L. Zanier, S. Perez-Gutthann, and F. Barbone. Validation of Primary and Secondary ICD9CM codes for Upper Gastrointestinal Complications in Friuli Venezia Giulia, Italy.
Mitra, D., P. Trask, S. Iyer, S. Candrilli, and J. Kaye. A Multi-country Retrospective Study of Patient Characteristics and Treatment Patterns in Chronic Myeloid Leukemia.
Sood, V., L. Braun, S. Hogue, K. Davis, C. Copley-Merriman, and B. Lieberman. Chronic Kidney Disease Burdens Patients, Health Care Systems, and Employers.
Spinner, D.S., D. Mladsi, J. Walter, R. Ziemiecki, M. Stafford-Smith, J. Taekman, and E. Faulkner. Clinical Trial Learning Curves May Impact Both Clinical and Economic Outcomes and Influence Health Technology Assessment and Reimbursement Decision Making.
Earnshaw, S.R., C.L. McDade, G. Zanotti, R. Farkouh, and D. Strutton. Cost-effectiveness of 2+1 Dosing of 13-Valent Pneumococcal Conjugate Vaccine Compared With 2+1 Dosing of 10-Valent Conjugate Vaccine in Preventing Pneumococcal Disease in Canada.
Clark, M., A. Hofmann, M. Tabberer, and S. Martin. Development and Content Validity of the COPD Device Preference Questionnaire.
Mohamed, A.F., F. Johnson, B. Hauber, B. Lescrauwaet, and M. Saylan. Do Patients and Physicians Have Similar Preferences for Chronic Hepatitis B Treatment Outcomes in Turkey?.
Hicks, K.A., S. Karve, A. Vlahiotis, S. Frazee, Y. Tian, and S.R. Earnshaw. Estimation of Increases in Direct Medical Expenditures Associated With Medication Nonadherence and Potential Savings From Increased Adherence.
Stull, D., and K. Houghton. Examining Variability in Depression Among Pre-Retirees: Innovative Analytic Methods Applied to Observational Data.
Gonzalez, J., R Johnson, M.C. Runken, and C. Poulos. Generalized Healthy-Time Equivalentsfor Migraine-Treatment Outcomes From Choice-Experiment Trade-off Preferences.
Hauber, B., S. Han, J.C. Yang, I. Gantz, K. Tunceli, J. Gonzalez, K. Brodovicz, C. Alexander , M. Davies, K. Lento, Q. Zhang, and L. Radican. How Much Do Patients with Type 2 Diabetes Value Improvements in Dosing Convenience? Results From a Conjoint Study.
Johal, S., C. Knight, M.J. Bell, and S. Ralston. Long-Term Fiscal Implications of MEPACT in the Treatment of High-Grade Nonmetastatic Osteosarcoma: A Budget-Impact Model and a Lifetime Tax Perspective.
Bridges, J.F.P., A. Mohamed, A. Woehl, H. Finnern, and B. Hauber. Patient Preferences for Non-Small Cell Lung Cancer Treatments.
Palsgrove, A., K. Houghton , A. Hareendran, M. Schaefer, J. Setyawan, M. Mocarski, R. Carson, and B. Make. The Development of the Early Morning Symptoms of COPD Instrument (EMSCI).
Mitra, D., and S.D. Candrilli. Acute Lymphocytic Leukemia–Related Inpatient Care Among Pediatric Patients in the United States.
Lancon, C., D.B. DiBenedetti, S.E. Lewis, K.A. David, N. Danchenko, and C. François. Assessing the Impact of Major Depressive Disorder (MDD) on Family Functioning: Development of the Depression and Family Functioning Scale.
Spinner, D.S., J.W. Walter, M.A. Vazquez-Gragg, T. Bloise, M. Stafford-Smith, E. Faulkner, and J. Taekman. Clinical Trial Learning Curves Affect Outcomes Measurement, Patient Safety, and Trial Success: Contributing Factors and a Potential Solution in Clinical Trial Simulation.
Bell, M.J., J.D. Miller, M. Namjoshi, and M.W. Russell. Comparative Budget Impact of Formulary Inclusion of Zoledronic Acid and Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases.
Candrilli, S.D., S.J. Karve, and P.E. Wirth. Complications Arising During Hospitalization for Hemorrhagic or Ischemic Stroke: Evidence From a Large Administrative Database.
Svedsäter, H., J. Locklear, S. Johal, and I. Özer-Stillman. Cost-effectiveness and budget impact of adjunct quetiapine fumarate extended-release in patients with major depressive disorder with an inadequate response to previous therapy.
Lukac, M., C. Knight, J. Bielik, D. Tomek, V. Foltán, M. Bojnický, and A. Kovac. COST-UTILITY ANALYSIS OF DIENOGEST VERSUS GnRH ANALOGUE IN THE TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN IN SLOVAKIA.
Lescrauwaet, B., A.F. Mohamed, F.R. Johnson, and A.B. Hauber. Do Patients and Physicians Have Similar Preferences for Health Care Decisions Involving Uncertain Outcomes for Chronic Hepatitis B in Germany and Turkey?.
Coon , C.D., L.D. Mcleod, L.M. Arnold, A. Chandran, and S. Martin. Evaluating the Screening Ability of Patient-Reported Outcome Instruments.
Faulkner, E., D.S. Spinner, and M. Fernandez. Health outcomes and economic research for cellular therapies and regenerative medicines: Lessons from a US Health Technology Assessment and Reimbursement Analysis.
Coleman, C., S. Chang, K. Copley-Merriman, C.J. Masaquel, and J. Hubble. Health-Related Quality-of-Life Improvements With Dysport in Cervical Dystonia.
Meyers, J.L., and S. Meyers. Inpatient Costs of Low Birth Weight and Pre-Term Infant Stays in the United States in 2008.
Dalal, A.A., L. Nelson , T.M. Gilligan, L.D. Mcleod, S.E. Lewis, and C. DeMuro. Measurement Comparability Between Paper and Alternate Versions: Recommended Assessment Steps Using the Lung Function Questionnaire as an Example.
Garrison, L., B. Levitan, and F.R. Johnson. Pharmaceutical Benefit-Risk Assessment: What Should We Do in the Absence of Regulatory Guidance?.
Knight, S., A. Mohamed, F. Johnson, D.A. Marshall, U. Ladabaum, K. Phillips, and J.M.E. Walsh. Preferences for Genetic Testing to Assess Colon Cancer Risks.
Mordin, M., M. Clark, C. DeMuro, E.D. Evans, K. Copley-Merriman, S. Fehnel, and A. Gnanasakthy. PRO label claims: an analysis based on a review of PROs among NMEs and BLAs 2006–2010.
DeMuro, C., M. Mordin, E.D. Evans, K. Copley-Merriman, S. Fehnel, and A. Gnanasakthy. Reasons for rejection of PRO label claims: an analysis based on a review of PRO use among new molecular entities and biologic license applications 2006–2010.
Mauskopf, J., C. Chirila, C.J. Masaquel, K.S. Boye, L. Bowman, J. Birt, and D.B. Grainger. The Relationship Between Financial Impact and the Likelihood of Drug Reimbursement in the Australian Health Care System.
Gilligan, T.M., L. Nelson , A.A. Dalal, and L.D. Mcleod. Visually Evaluating the Measurement Comparability Between Paper-Based and Alternate Versions of Administration of the Lung Function Questionnaire.
Karve, S., M. Markowitz, J. Panish, S. Candrilli, I. Cosmatos, and L. Alphs. Assessing Health Care Utilization and Costs Among Hospital-Discharged Patients With Schizophrenia.
Markowitz, M., S. Karve, J. Panish, S. Candrilli, I. Cosmatos, and L. Alphs. Evaluating Antipsychotic Adherence Patterns Among Medicaid-Enrolled Hospital-Discharged Patients With Schizophrenia.
Amonkar, M.M., B. Sherrill, and X. Zhou. A Review of the Impact of Lapatinib on Health-Related Quality of Life of Patients With Newly Diagnosed and Refractory Metastatic Breast Cancer.
Chung, R.T., A. Bisceglie, F.F. Poordad, T. Hassanein, X. Zhou, E. Lentz, A. Prabhakar, and F.M. Hamzeh. Association of Host Pharmacodynamic Effects and Virologic Response to Peginterferon Alfa-2a/Ribavirin in Patients with Chronic Hepatitis C.
Nicandro, J., P. Tennis, P. Shin, P. Hickman, L. Bennett, K.A. Hollis, and E. Andrews. ONE-YEAR TREATMENT CONTINUATION WITH ALOSETRON IS HIGH IRRESPECTIVE OF IBS-D SEVERITY CRITERIA.
Chirila, C., D. Odom, G. Devercelli, S. Khan, B. Sherif, J. Kaye, I. Molnar, and B. Sherrill. Meta-Analysis of the Validity of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Metastatic Colorectal Cancer Trials.
Faulkner, E., M. Burken, L. Kelley, and R. Richner. Market Access Challenges for Device and Diagnostic Companies: Adaptive Approaches for Value Characterization.
Midkiff, K., A. Gilsenan, Y. Wu, D. Masica, and E. Andrews. Characteristics of Adult Osteosarcoma Patients: Results From an Ongoing Postmarketing Drug Safety Surveillance Study.
Williams, V.S.L., R.T. Carson, L.M. Nelson, J. MacDougall, S.E. Fehnel, B. Lewis, and J.M. Johnston. Application of Exploratory Factor Analysis to Support the Conceptual Framework of PRO Measures: Results From a Phase 2 Study of Irritable Bowel Syndrome With Constipation.
Norquist, J.M., C.J. Girman, S. Fehnel, C. DeMuro, and N. Santanello. Choice of Recall Period for Patient-Reported Outcome Measures: Criteria for Consideration.
Gilsenan, A., E. Andrews, and K.A. Hollis. Characterization of Current Risk Evaluation and Mitigation Strategies.
Tennis, P., K.J. Rothman, R. Bohn, H. Tan, M.S. Anthony, A. Zavras, and B. Calingaert. Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw.
Hollis, K.A., P. Tennis, J. Nicandro, E. Chuang, C.T. Sweeney, L. Bennett, and E. Andrews. Temporal Trends in Compliance With the Alosetron Risk Management Program.
Hollis, K.A., B. Calingaert, M. Price, E. Andrews, L. Moy, M. Kooijmans, L. Cristiano, and C. Bozic. Tysabri TOUCH Prescriber Program Risk Management Program (RiskMAP) Surveys.
Rycroft, C.E., I.V. Pearson, S. Khan, and A.E. Heyes. A Tale of Four Countries: Comparing Reimbursement Submission Requirements in Ireland, England, Wales, and Scotland.
Rycroft, C.E., O. Leeuwenkamp, T. Heikkinen, N. Principi, J. Herz, A. Moren, and S.M. Beard. Economic and Clinical Burden of Paediatric Influenza in Nine European Countries.
Candrilli, S.D., S.H. O'Brien, and R. Balkrishnan. Economic Outcomes Associated With Hydroxyurea Adherence Among Pediatric Medicaid Enrollees With Sickle Cell Disease.
Fehnel, S., C.M. Ervin, B. Lewis, R.T. Carson, and J.M. Johnston. Identifying Endpoints for Irritable Bowel Syndrome (IBS) Clinical Trials: Incorporating the Patient's Voice.
Mohamed, A.F., A. Hauber, and B. Lescrauwaet. Is it Possible to Obtain Willingness-to-Pay Estimates in Europe? A Validity Test of Stated Preferences for Hepatitis B Treatments.
Karve, S., D. Misurski, J.M. Miller, and K.L. Davis. Long-Term Economic and Clinical Burden of Complicated Invasive Meningococcal Disease: Evidence From a United States Managed Care Population.
Meyers, J., and S.D. Candrilli. Patient Characteristics and Charges Associated With Emergency Department Visits Among Patients With a Diagnosis of Restless Legs Syndrome.
Mohamed, A.F., B. Hauber, A. Masterson, and B. Lescrauwaet. Patient Preferences for Benefits, Risks, and Weight of Evidence Associated With Hepatitis B Treatments.
Johnson, F.R., J. Gonzalez, and B. Hauber. Patients' Stated Health Outcome Preferences for Confounded Patient-Reported Outcome Domains for Osteoarthritis.
Bridges, J.F.P., S. Taylor, N. Arden, B. Hauber, F.R. Johnson, D. Watson, P. Mavros, J. Pellisier, P. Peloso, S. Sen, A.F. Mohamed, and J.M. Gonzalez. Physicians' Stated Preferences Over Benefits and Risks Associated With NSAID Use in Patients With Osteoarthritis in UK.
Mladsi, D., S. Earnshaw, N. Akashi-Ronquest, and M. Keith. Proposed Methods for Conducting Sensitivity Analyses on Threshold-Derived Estimates of Value-Based Price and Product Profi les of Early Stage Drugs.
Mladsi, D.. Review of Utility Estimates in Atopic Dermatitis.
Beard, S.M., T.K. Le, Y. Zhao, and N. Roskell. The Cost-effectiveness of Duloxetine in the Treatment of Fibromyalgia in the United States.
Meyers, J., D. Mitra, J. Doan, and C. Leeflang. The Role of Patient Selection Criteria in Identifying Ovarian Cancer Patients in a Retrospective Database Analysis.
Mladsi, D., S. Earnshaw, N.A. Ronquest, and M. Keith. Threshold Pricing Model: Not Just Another Cost-effectiveness Model.
Rinaldi, F., S. Hwang, D. Strutton, S. Earnshaw, and R. Farkouh. Clinical and Economic Impact of 13-Valent Pneumococcal Conjugate Vaccination In Singapore and Hong Kong.
Talbird, S.E., K. Bell, J.B. Graham, L. Deal, and J. Mauskopf. Cost-effectiveness Analysis for Treatment of Symptomatic Uterine Fibroids Among Premenopausal Women Seeking to Retain Their Uterus.
Jackson, D., S. Earnshaw, R.A. Farkouh, and L.H. Schwamm. Cost-effectiveness of Perfusion Imaging With Computed Tomography to Identify Patients for Intravenous Thrombolysis: A Hospital Perspective.
Earnshaw, S., M. Pignone, A.M. Fendrick, and J. Scheiman. Cost-effectiveness of Proton Pump Inhibitors for Prevention of Gastrointestinal Adverse Events When Using Aspirin for Primary Cardiovascular Prevention.
Colosia, A.D., S.B. Khan, G. Peltz, G. Pohl, E. Liu, and J.A. Kaye. ELECTRONIC MEDICAL RECORDS: QUALITY CANCER CARE AND COST-EFFECTIVENESS.
West, N., M. Leung, M. Halpern, and E.C. Faulkner. Evidence Used During Pharmaceutical Technology Assessment.
Hauber, B., A.F. Mohamed, and M.P. Neary. How Much Do Patients with Renal Cell Carcinoma (RCC) Value Progression-free Survival ABSTRACT 27007 in Medical Decision Making—Results from a Benefit-Risk Conjoint Study.
Davis, K.L., D. Mitra, C. Leteneux, B. Bapat, and C. Naujoks. Medical Service Utilization and Costs by Disease Severity, Sustained Viral Response, and Genotype in European Patients with Chronic Hepatitis C Virus.
Johnson, F.R., B. Hauber, J. Gonzalez, B. Levitan, and P. Coplan. Patient Preference Weights for Benefi t-Risk Analysis: A Statin Case Study.
Mordin, M., S.E. Lewis, A. Gnanasakthy, C. Demuro-Mercon, K. Copley-Merriman, and S. Fehnel. Patient-Reported Outcomes as Mentioned in Product Development Guidance.
Ervin, C.M., S. Fehnel, R. Carson, C. Kurtz, S. Shiff, and J. Johnston. Selecting Chronic Constipation (CC) Clinical Trial Endpoints: Incorporating the Patient's Voice.
Bapat, B., K.L. Davis, K. Bell, L. Deal, and S.E. Talbird. Treatment Patterns and Economic Burden of Uterine Fibroids in a United States Managed Care Database.
Davis, K.L., D. Mitra, C. Leteneux, B. Bapat, and C. Naujoks. Utilization and Cost of Peginterferon Plus Ribavirin Combination Therapy in the Management of Chronic Hepatitis C Virus in Europe.
Gilsenan, A., E.B. Andrews, B. Calingaert, D.A. Crozier, and A. Vanderpuije. Evaluation of Current Risk Evaluation and Mitigation Strategies.
Tennis, P., A. Zavras, C. Laskarides, and H. Tan. Predictive Value of ICD and CPT Codes for Identifying Osteonecrosis of the Jaw.
Gilsenan, A., R.H. Stanford, C. Bui, R.M. Ziemiecki, and H. Ortega. Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Results from the Asthma Control Characteristics and Prevalence Survey Study (ACCESS).
Midkiff, K., A. Gilsenan, R. Martin, Y. Wu, D. Masica, and E.B. Andrews. The Impact of Patient Access Pathways on Postmarketing Drug Safety Studies Using Cancer Registry Data.
Varas-Lorenzo, C., C. Johannes, L. McQuay, K. Midkiff, M.R. Stang, and D. Fife. Validation of Serious Ventricular Arrhythmias in an Adminisrative Database.
Blum, J., S. Hu, D.M. Odom, B. Sherrill, and S. Gluck. Effect of Age on Overall Survival in Capecitabine - treated Patients with Metastatic Breast Cancer.
Sherrill, B., Y. Wu, M. Amonkar, M. Arbushites, and A. Di Leo. First-Line Treatment With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients with ErbB2+ (HER2+) Metastatic Breast Cancer: Quality of Life Analyses Using Repeated Measures and Pattern Mixture Models.
Sherif, B.N., B. Sherrill, M. Amonkar, Y. Wu, J. Maltzman, L. O'Rourke, and S. Johnston. Lapatinib Plus Letrozole Compared With Letrozole Alone as First-Line Therapy in Hormone Receptor Positive HER2+ Metastatic Breast Cancer: A Quality of Life Analysis.
Gluck, S., C. Russell, J. O'Shaughnessy, G. Yuan, D.M. Odom, B. Sherrill, and J. Blum. Relationship Between Survival and Estrogen Receptor Status in Patients With Metastatic Breast Cancer Treated With Capecitabine and Docetaxel: An Exploratory Data Analysis.
Sherrill, B., B.N. Sherif, M. Amonkar, Y. Wu, J. Maltzman, L. O'Rourke, and S. Johnston. Quality of Life and Quality-Adjusted Survival (Q-TWiST) in Patients Receiving Lapatinib Plus Letrozole as First-Line Therapy in Hormone Receptor Positive, HER2+ Metastatic Breast Cancer.
Faulkner, E.C.. The Evolution of Personalized Medicine: The Role of Pharmacogenomics in Managed Care.
Sherrill, B., M. Amonkar, B. Sherif, J. Maltzman, L. O'Rourke, and S. Johnston. An Exploration of the Association of QOL Scores With Tumor Progression Status in First-Line HR+, HER2+ MBC Patients Treated With Lapatinib Plus Letrozole or Letrozole Alone.
Tennis, P., E. Andrews, C. Ambrose, S. Toback, and M.D. Rousculp. A Postmarketing Commitment to Evaluate the Frequency of Use and Safety of Live Attenuated Influenza Vaccine Use in Non-Recommended Populations Less Than 59 Months of Age.
Johnson, F.R.. Patient and Physician Benefit-Risk Preferences: Evidence From 7 Studies.
Johnson, F.R.. Stated Benefit-Risk Tradeoff Preferences From Conjoint Analysis.
Knight, C., A. Colligs, and J. Lipinski. A Budget Impact Analysis of Dienogest in Treating Endometriosis-Associated Pelvic Pain in Germany.
Rycroft, C.E., S. Beard, O. Leeuwenkamp, and S. Moren. Burden of Paediatric Influenza in Europe: A Gap Analysis.
Lloyd, A., J.F.P. Bridges, and F.R. Johnson. Classifying patient reported outcomes: Developments in the field suggest a new taxonomy.
Brogan, A., S. Soorapanth, V. Donatz, A. Hill, and E. Smets. Comparative Cost-Efficacy Analysis of Darunavir/r and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in Germany.
Earnshaw, S., C.L. McDade, L. Black, and M. Kattan. Cost-effectiveness of Chemoprevention With Dutasteride Based on Results From the REDUCE Clinical Trial.
Farkouh, R., M. Wilson, M.L. Tarrants, J. Castelli-Haley, and C. Armand. Cost-effectiveness of Rasagiline Compared With Other First-Line Treatment Options for Early Parkinson's Disease in the United States.
Wolowacz, S., M. Jhaveri, and K. Tangirala. Cost-Utility Model to Evaluate Adjuvant Chemotherapy for Early Breast Cancer in the United States.
Mauskopf, J., J.B. Graham, J. Bae, and C. Gaich. Impact of Including Prasugrel on the Formulary for Patients Who Undergo Percutaneous Coronary Intervention for Acute Coronary Syndrome.
de Cambra, S., D. Mladsi, and S. Neale. International Payer Research: Comparing and Contrasting Payer Roles and Research Methods in Canada, Spain, and the UK.
Mladsi, D., S. de Cambra, A. Gilabert-Perramon, and E.C. Faulkner. Orphan Drug Funding: A Model for Personalized Medicine?.
de Cambra, S., D. Mladsi, S. Neale, and E.C. Faulkner. Reimbursement of Active Immunotherapeutics: An Analysis Based On a Study of Current Reimbursement Approaches.
Zimovetz, E., and S. Wolowacz. Reviewer's Checklist for Assessing the Quality of Decision Models.
Kauf, T., K.L. Davis, S. Earnshaw, E.A. Davis, and M.E. Watson. SPILLOVER ADHERENCE EFFECTS OF FIXED-DOSE COMBINATION HIV THERAPY.
Wolowacz, S., M. Samuel, V.K. Brennan, J. Jasso-Mosqueda, and I. van Gelder. The Cost of Illness of Atrial Fibrillation: A Systematic Review.
Faulkner, E.C.. The Devil is in the Details: International Comparison of Technology Assessment Processes and Payer Uptake of Personalized Medicine and Implications for the Field.
Wolowacz, S.. The United Kingdom's National Institute for Health and Clinical Excellence: NEW DEVELOPMENTS.
Mauskopf, J., C. Schmitt, K.S. Boye, P.L. McCollam, M.D. Juniper, and J.A. Birt. Adherence to Guidelines for Sensitivity Analysis: Cost-Effectiveness Analyses of Dual Oral Antiplatelet therapy.
Juniper, M.D., C. Gaich, R. Frear, and B. Sweet. Adhering to Multiple Guidelines for Preparation of Formulary Submission Dossiers: Aligning with Payer Expectations.
Soorapanth, S., A. Brogan, J. Mrus, and E. Smets. Comparative Cost-Efficacy Analysis of Darunavir/r for First-Line Treatment of HIV Infection in the United States.
Wolowacz, S.E., N.S. Roskell, J.M. Plumb, A. Clemens, P. Robinson, G. Dolan, and I.J. Brenkel. Cost-effectiveness of Dabigatran Etexilate 150mg for the Prevention of Venous Thromboembolism in Patients Aged Over 75 Years Undergoing Total Hip or Knee Arthroplasty.
Wolowacz, S., and N. Roskell. Cost-effectiveness of Dabigatran etexilate 150mg for the Prevention of Venous Thromboembolism in Patients Undergoing Total Hip or Knee Arthroplasty with Moderate Impairment of Renal Function.
Wolowacz, S.E., N.S. Roskell, J.M. Plumb, A. Clemens, P. Robinson, G. Dolan, and I.J. Brenkel. Cost-effectiveness of Dabigatran Etexilate 150mg for the Prevention of Venous Thromboembolism in Patients Undergoing Total hip or Knee Arthroplasty with Moderate Impairment of Renal Function.
Farkouh, R.A., M.R. Wilson, M. Tarrants, J. Castelli-Haley, and C. Armand. Cost-Effectiveness of Rasagiline Versus Ropinirole Extended Release in Delaying Levodopa in the Treatment of Early Parkinson's Disease in the United States.
Nelson, L.M., L.D. Mcleod, L.J. Lee, C.D. Hill, and C.T. Sweeney. Effects of Insulin Therapy on the Diabetes Symptom Checklist-Revised (DSC-R): Data from a Large Insulin Clinical Trial.
Mordin, M.M., M. Clark, C.A. Siersma, K. Copley-Merriman, and A. Gnanasakthy. Impact Of The FDA Draft Guidance on Patient Reported Outcomes (PRO) Label Claims for Approved Drug Products in the US: Has It Made a Difference?.
Gilligan, T.M., and C.M. Hill. Longitudinal Data Exploration With Stacked Cumulative Percent Plots for Categorical Data.
Mohamed, A.F., A.B. Hauber, J. Medjedovic, and C. Beam. Patient Preferences and Stated Adherence for Hepatitis C Virus Treatments.
Copley-Merriman, K., S.M. Barrows, J. Whiteley, and A.M. Barrett. Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool.
Sherrill, B., M. Amonkar, B.N. Sherif, J. Maltzman, L. O'Rourke, and S. Johnston. A Q-TWiST Analysis of Lapatinib Plus Letrozole Compared With Letrozole Alone as First-Line Therapy in Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC).
Goldberg, J.F., L.D. Mcleod, S.E. Fehnel, L.R. Hamm, and K. Gilchrist. Development and Evaluation of a New Patient-Reported Instrument: the Bipolar Functional Status Questionnaire.
Burstein, H., K.M. Blackwell, Y. Wu, A. Storniolo, H. Rugo, M. Amonkar, C.S. Ellis, G. Sledge, J. Baselga, and J. O'Shaughnessy. Impact of Lapatinib Plus Trastuzumab Versus Single-Agent Lapatinib on Quality of Life of Patients With Trastuzumab-Refractory HER2+ (ErbB2+) Metastatic Breast Cancer.
Sherrill, B., A. Di Leo, M. Amonkar, M. Koehler, and M. Arbushites. A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis Comparing First-Line Therapy With Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for Patients With HER2+ Metastatic Breast Cancer (MBC).
Kaufman, B., T. Bachelot, Y. Wu, M. Amonkar, t. zaks, V. Salazar, P. Viens, and S. Johnston. Lapatinib Monotherapy in HER2+ Relapsed or Refractory Infl ammatory Breast Cancer (IBC): Quality of Life (QOL) Assessment.
Rugo, H., P. Kaufman, M.U. Yood, A. Brufsky, M. Mayer, E. Tan-Chlu, D. Yardley, M. Birkner, L. Wang, M. Brammer, and D. Tripathy. registHER: An Observational Cohort Study of Survival of Patients with HER2-Positive Metastatic Breast Cancer and Use of Trastuzumab Following Progression.
Wu, Y., H. Burstein, K.M. Blackwell, A. Storniolo, H. Rugo, M. Amonkar, C.S. Ellis, G. Sledge, J. Baselga, and J. O'Shaughnessy. Lapatinib Plus Trastuzumab Versus Lapatinib Monotherapy in Trastuzumab-Refractory ErbB2+ Metastatic Breast Cancer Patients: Quality of Life Assessment.
Zhou, X., D. Cella, A. Segreti, D. Cella, D. Cameron, C. Geyer, M. Amonkar, S. Stein, and M. Walker. Effect of Lapatinib Plus Capecitabine on Quality of Life Compared to Capecitabine Alone in ErbB2-Positive Metastatic Breast Cancer: An Exploratory Analysis.
Sherrill, B., M.M. Amonkar, Y. Wu, C. Hirst, S.H. Stein, M.D. Walker, and J. Cuzick. Disease Progression as a Predictor of Overall Survival in Metastatic Breast Cancer: A Meta-analysis.
Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib + Capecitabine vs. Capecitabine alone for ErbB2+ Metastatic Breast Cancer: Quality-of-Life Assessment.
Zhou, X., A. Segreti, D. Cella, D. Cameron, C. Geyer, M.M. Amonkar, S.H. Stein, and M.D. Walker. Lapatinib Plus Capecitabine Versus Capecitabine Alone for ErbB2-Positive Metastatic Breast Cancer: Quality-of-Life Assessment.
Wu, Y., A. Segreti, D. Cella, A. DiLeo, M.M. Amonkar, M. Koehler, M. Arbushites, and M.D. Walker. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone for First-Line Metastatic Breast Cancer in ErbB2-Positive Patients: Quality-of-Life Results.
Perez-Gutthann, S.. Lessons Learned from Epidemiologic Studies and Clinical Trials.
Gilsenan, A.W., A. Ladner, C. Varas-Lorenzo, T. Kold Olesen, C. Karup, and E.B. Andrews. Incidence of Cardiovascular and Cerebrovascular Events Among Men With Prostate Cancer.
DeStefano, F., C.D. Heath, D.B. Currivan, and S.F. Wetterhall. Influenza Vaccination Among Adults in Four North Carolina Counties, 2007–2008.
Midkiff, K., C.B. Johannes, and A.K. Mohan. Utility of Multiple Databases in a Surveillance Program for Prescription Narcotic Analgesics.
Knight, C.J.. A Systematic Review of the Efficacy of Recombinant Activated Factor VII and Activated Prothrombin Complex Concentrate in the On-Demand Treatment of Minor to Moderate Bleeding Episodes for Haemophilia Patients With Inhibitors.
Odom, D., G. Devercelli, L. Bennett, M. Peeters, M. Wolf, and R. Amado. Health-Related Quality of Life (HRQOL) and Colorectal Cancer (CRC) Symptoms in Metastatic CRC: Panitumumab Plus Best Supportive Care (BSC) Versus BSC Alone by KRAS Tumor Status.
Mitra, D., and S.D. Candrilli. Inpatient Costs and Outcomes Associated With Hepatitis C, Human Immunodefi ciency Virus, and Co-Infection With Both in the United States.
Brennan, V.K., and S.E. Wolowacz. A Systematic Review of Breast Cancer Utility Weights.
Barrett, A.M., A.D. Colosia, K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Costs in Nine Countries.
Barrett, A.M., K.S. Boye, and O. Oyelowo. Burden of Obesity: 10-Year Review of the Literature on Obesity Prevalence in Nine Countries.
Davis, K.L., D. Mitra, J. Medjedovic, C. Beam, and V.K. Rustgi. Direct Economic Burden of Chronic Hepatitis C Virus in a Large Managed Care Population.
Davis, K.L., D. Mitra, and S. Kotapati. Direct Economic Burden of High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.
Mitra, D., K.L. Davis, J. Medjedovic, C. Beam, and V.K. Rustgi. Health Care Utilization and Costs Associated with Chronic Hepatitis C in a Managed Care Population.
Mitra, D., S. Candrilli, K.L. Davis, and B. Bapat. Inpatient Costs and Outcomes Associated With Chronic Hepatitis C-Related Complications in the United States.
Copley-Merriman, C., S.E. Fehnel, J. Chandler, and D. Wild. Obtaining a Patient-Reported Outcomes Label Claim: What Evidence Do You Need?.
Kotapati, S., D. Mitra, K.L. Davis, and U. Iloeje. Predictors of Treatment Choice in High-Risk and Metastatic Melanoma: Evidence From Linked Electronic Medical Records and Administrative Claims Data.
Mohamed, A.F., F.R. Johnson, A.B. Hauber, D. Meddis, and S. Wagner. Preferences for Onset of Effect of Combination Maintenance Medication Among Asthma Patients.
Hauber, A.B., A.F. Mohamed, F.R. Johnson, H. Falvey, and E. Snyder. Preferences for Oral Antidiabetic Agents Among People With Type 2 Diabetes.
Mitra, D., K.L. Davis, S. Kotapati, and U. Iloeje. Real-World Treatment Patterns in High-Risk and Metastatic Melanoma: Evidence From the SEER-Medicare Linked Database.
Candrilli, S., R. Balkrishnan, and S.H. O'Brien. The Effect of Injury Severity on the Incidence and Resource Utilization-Related Outcomes of Deep Vein Thrombosis Among Pediatric Trauma Admissions in the United States.
DiBenedetti, D., and C.D. Hill. Adherence Among Patients with Parkinson's Disease Taking Ropinirole Immediate Release At Least Three Times Daily.
DiBenedetti, D., J.A. Sollano, and R.L. Kolotkin. The Impact of Being Overweight on Health-Related Quality of Life in Type 2 Diabetic Patients: Patient Interviews.
Sherrill, B., C. Hirst, Y. Wu, M.M. Amonkar, and S.H. Stein. Retrospective Pooled Analysis to Assess Correlation Between Time to Progression and Overall Survival in Patients With Breast Cancer.
Mauskopf, J., A.J. Brogan, C. Malmberg, and P. Hwang. Cost-Effectiveness of Darunavir for the Management of HIV-Infected, Treatment-Experienced Adults in Canada.
Sherrill, B.H., A.A. Allshouse, M.M. Amonkar, and S.H. Stein. Lapatinib plus capecitabine versus capecitabine alone for metastatic breast cancer: Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST).
Sherrill, B., A.A. Allshouse, and S.H. Stein. Lapatinib Plus Capecitabine Versus Capecitabine Alone for Metastatic Breast Cancer: Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST).
Graham, C.N., S.R. Earnshaw, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget Using Census Region and State-Specific Smoking Estimates.
Earnshaw, S.R., V. Sikirica, N.S. Roskell, P.R. Shannon, S. Beard, J. Schein, D. Doshi, and C. Janagap. Economic Analysis of Short-Course Levofloxacin Versus Amoxicillin/Clavulanate in Treating Acute Bacterial Exacerbations of Chronic Bronchitis.
Davis, K.L., S.D. Candrilli, and H.M. Edin. Prevalence and Cost Impact of Nonadherence with Antiepilepsy Drugs Among Adults in a Managed Care Population.
Candrilli, S.D., E. Lee, S.S.K. Tang, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Cardiovascular Risk in US Urban Hispanic Populations: Regional Data From Community Outreach Programs.
Tang, S.S.K., E. Lee, S.D. Candrilli, H.J. Laird, S.S. Levy, S. Bassin, and N.D. Wong. Prevalence, Treatment, and Control of Hypertension and/or Dyslipidemia Among Hispanic Adults in US Communities.
Lee, E., S.S.K. Tang, S.D. Candrilli, S. Bassin, H.J. Laird, S.S. Levy, and N.D. Wong. Regional Differences in the Prevalence of Hypertension and Dyslipidemia in US Urban Hispanic Populations.
Hirst, C., and E. Andrews. International Therapeutic Risk Management.
Sherrill, B., A.A. Allshouse, M.M. Amonkar, M.D. Walker, and S.H. Stein. A Comparison of Lapatinib Plus Capecitabine Versus Capecitabine Alone for Quality-Adjusted Survival in Metastatic Breast Cancer: a Q-TWiST Analysis.
Beard, S.. Developing Health Economic Models for Submission to Health Authorities as Evidence of Product Value.
Midkiff, K., A. Gilsenan, R. Martin, D.N. Masica, and E. Andrews. Characteristics of Patients in a Postmarketing Osteosarcoma Surveillance Study.
Wang, J., B. Sherrill, and W. Irish. Determining Sample Size For Postmarketing Surveillance of Rare Adverse Events.
Gilsenan, A.W., K. Midkiff, Y. Wu, R. Martin, D.N. Masica, and E. Andrews. Factors Associated With Interview Completion Rates in a Surveillance Study of Osteosarcoma and Antecedent Exposures.
Perez-Gutthann, S.. Risk Management Planning: An industry viewpoint – Achievement and Problems.
Midkiff, K., C.B. Johannes, and A.K. Mohan. Strengths and Limitations of Drug Abuse Warning Network Data Used in a Surveillance Study.
Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Identification of Pregnancies Within The Full Feature-General Practice Research Database.
Devine, S.T., S. West, E. Andrews, P. Tennis, S. Eaton, J. Thorp, and A. Olshan. The Validation of Neural Tube Defects in the General Practice Research Database.
Johnson, F.R., A.B. Hauber, A.F. Mohamed, C. Leibman, H.M. Arrighi, A.S. Zbrozek, and P. Coplan. Alzheimer's Disease Progression Healthy-Year Equivalents: Stated Risk-benefit Trade-off Preferences.
Zyczynski, T.M., S.M. Beard, S.R. Earnshaw, and C.L. McDade. Cost-effectiveness Analysis of the Use of Iodixanol Compared to Iohexol in the United Kingdom.
Graham, J.B., S.R. Earnshaw, J. Castelli-Haley, M. Oleen-Burkey, and K.P. Johnson. Cost-effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis in the Presence of Long-Term Clinical Evidence.
Leeuwenkamp, O., R. Morlock, C. Bell, A.J. Brogan, and J. Mauskopf. Costs and Outcomes of Atypical Antipsychotics for the Treatment of Acute Schizophrenia.
Mohamed, A.F., A.B. Hauber, F.R. Johnson, M.E. Watson, and J.E. Hernandez. Incorporating Probabilistic Attributes in a Stated-Choice Risk-Benefit Survey.
Mitra, D., K.L. Davis, S.D. Candrilli, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Pediatric Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.
Sherrill, B.H., C. Hirst, M.M. Amonkar, and S.H. Stein. Correlation Between Time to Progression and Overall Survival in Patients With Metastatic Breast Cancer.
Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage over a Two-Year Managed Care Enrollment Period.
Mitra, D., K.L. Davis, and R. Baran. Health Care Utilization and Costs Associated With Constipation (C-ONLY) and Co-Occurring Irritable Bowel Syndrome and Constipation (IBS+C) Compared to Migraine in a Large Managed Care Population.
Ozdemir, S., A.F. Mohamed, G. Huiber, and F.R. Johnson. How Good Is Good Enough? Internal Validity of Stated Preferences for Drug Therapies.
Candrilli, S., K.L. Davis, D. Mitra, B.J. Tortella, and A.V. Joshi. Inpatient Costs and Outcomes Associated With Traumatic Injury in the United States by Injury Severity and Trauma Center Designation.
Mcleod, L.D., S.E. Fehnel, L.J. Zografos, S.D. Sander, T.G. Curtis, and H. Shah. The Impact of Restless Legs Syndrome on Various Dimensions of Life: Results of a Web-Based Patient Survey.
Perez-Gutthann, S.. Evaluación de Señales de Alerta en el contexto global de la Gestión de Riesgos.
Davis, K.L., S.D. Candrilli, A.V. Joshi, and B.J. Tortella. The Direct Economic Burden of Blunt and Penetrating Trauma Among the Elderly Population.
Perez-Gutthann, S.. What Have We Learned from Safety Cases for New Drug Development? Industry Responding to Learning from Safety Cases.
Davis, K.L., J.K. Allen, J. Kirsch, K.H. Davis, and H.M. Edin. The Prevalence of Treatment Non-Adherence Among Patients with Parkinson's Disease in a United States Managed Care Population.
Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. Healthcare Seeking Behavior Among Peri- and Post-Menopausal Women: Results from the US Population-Based MEPI Study.
Williams, R.E., D. DiBenedetti, X. Zhou, S.E. Fehnel, and R.V. Clark. The Menopause Epidemiology (MEPI) Study: Vasomotor Symptom Results from a Large Population-Based Study.
Earnshaw, S.R., A.V. Joshi, M.R. Wilson, and J. Rosand. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage.
Earnshaw, S.R., S.M. Beard, N.O. Lynch, A. Cooper, W. Cowell, and H. Middelhoven. A Comparison of the Cost-Effectiveness of Bisphosphonates Using Persistence Data from a UK Propsective RCT.
Candrilli, S., and J. Mackell. Effect of NCEP ATP III Guideline Revisions on the Prevalence of Dyslipidemia Among the Elderly: Evidence from NHANES.
Earnshaw, S.R., A.V. Joshi, and M.R. Wilson. Cost-effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Managed Care Perspective.
Earnshaw, S.R., and J. Gricar. Good Practices for High Quality Decision Analytic Models.
Davis, K.L., J. Mauskopf, W. Chow, J. Chao, and B. Seal. Titration and persistence with tamsulosin among men with benign prostatic hyperplasia in a large managed care population.
Graham, C.N., S.R. Earnshaw, D.G. Smith, S. Hogue, J. Gitchell, H. Marsh, W. Becker, and M. Saunders. Assessing the Impact of Smoking Cessation Therapies on a Managed Care Organization's Budget.
Davis, K.L., A.V. Joshi, B.J. Tortella, and S.D. Candrilli. The Direct Economic Burden of Blunt and Penetrating Trauma in a Managed Care Population.
Rubino, A., D. Mines, N.S. Roskell, P. Tennis, E. Andrews, and S. Welch. Risk of Suicide During Venlafaxine Treatment Compared with Citalopram, Fluoxetine, and Dothiepin Treatment: A Population-based Analysis in the United Kingdom.
Ozdemir, S., F.R. Johnson, C. Mansfield, S. Hass, and J. White. Are Crohn's Parents More Risk Averse Than Adult Patients? Acceptable Tradeoffs between Efficacy and Adverse-Event Risks.
Johnson, F.R., and G.L. Van Houtven. Evaluating Risk-Benefit Tradeoffs and Health-Related Utility: A Comparison of Standard Gamble and Conjoint Methods.
Johnson, F.R., S. Ozdemir, A.F. Mohamed, D. Marshall, and K. Philips. How Does price Matter in Healthcare Stated-Choice Surveys?.
Zlateva, G.P., J.C. Javitt, S.R. Earnshaw, A.M. Pliel, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-effectiveness Model for Age-related macular Degeneration: Comparing Early and Late Macugen Treatment.
Earnshaw, S.R., S.M. Beard, N.O. Lynch, and W. Cowell. Ibandronate in the treatment of postmenopausal osteoporosis: a cost-effectiveness analysis in the UK.
Mladsi, D.M.. Developing Health Economic Models for Assessing Cost-Effectiveness and Product Value.
Kauf, T.L., M.S. Saag, M. Kitahata, B. Gazzard, S.R. Earnshaw, C.N. Graham, E.A. Davis, A. Shearer, and J. Mauskopf. Simulation Modeling of Adherence and Resistance on Long-Term Outcomes in HIV.
Varas-Lorenzo, C., L. McQuay, S. Eaton, I. Saez-Lloret, M. Melero-Montes, D. Miller, and S. Perez-Gutthann. Characterization of US Adult Users of Antihypertensive Medications.
Gilsenan, A., X. Zhou, F. Coste, and A.A. Allshouse. Comparison of Data from a US National Survey (NHANES) with Data from a Cohort Recruited from the Internet.
Sanchez Matienzo, D., L.L. Lanza, L.J. McQuay, L. Gutierrez, and S. Perez-Gutthann. Descriptive Study of Users of Depo-Medroxyprogesterone Acetate (DMPA) in the MHRA GPRD.
Nyberg, F., S. Hada, and K.J. Rothman. Iressa and Interstitial Lung Disease (ILD) in Japan - Lessons from a Large Nested Case-Control Study to Evaluate a Safety Issue.
Johnson, F.R., S. Ozdemir, E. Andrews, S. Hass, D.P. Miller, J. White, C. Siegel, and B. Sands. Patients' Willingness to Accept Risk-Benefit Tradeoffs in Treating Crohn's Disease.
Rubino, A., L. McQuay, M. Kvasz, and P. Tennis. Population-Based Study of Time to Insulin After Failure of Oral Antidiabetic Therapy in Type 2 Diabetes in the UK.
Lanza, L.L., L. Wang, T. Simon, and W. Irish. Risk of Selected Outcomes After Solid Organ Transplantation: A Literature Review.
Rubino, A., S.J. Evans, and L. Smeeth. Risk of Stroke During Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the United Kingdom.
Rubino, A., N.S. Roskell, P. Tennis, D. Mines, S. Weich, and E. Andrews. Risk of Suicide During Venlafaxine and Comparator Antidepressants Treatment.
Wang, J., A.A. Allshouse, and W. Irish. Underestimation of Variance Due to Using Simple Random Sampling Statistical Methods Applied to Data Obtained from a Cluster Sampling Design.
Bell, C.F., J.B. Graham, S.R. Earnshaw, M. Oleen-Burkey, J. Castelli-Haley, and K. Johnson. Assessing the Cost-Effectiveness of Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis Based on Long-Term Data.
Candrilli, S.D., and J.A. Mauskopf. How Much Does a Day in the Hospital Cost?.
Kolotikin, R.L., R. Crosby, C. Radigue, and A.A. Allshouse. Impact of Abdominal Obesity on Health-Related Quality of Life.
Mauskopf, J.A., G.S. Simon, C. Nimsch, and A.A. Krishnan. Measurement of Utility Losses in Depression.
Bala, M.V., J.A. Mauskopf, and G.A. Zarkin. Presenting Uncertainty Around Cost-Effectiveness Estimates to Decision Makers: How Sure Are We?.
Johnson, F.R., and G.L. Van Houtven. Quantifying Patients' Risk-Benefit Tradeoff Preferences: A Conceptual and Empirical Comparison of Methods.
Earnshaw, S.R., C.N. Graham, M.M. Amonkar, and C. Barr. The Cost-Effectiveness of Ibandronate in the Treatment of Postmenopausal Osteoporosis in the US.
McCrink, L., S.M. Beard, and T. Le. The Relationship Between Health-Related Quality of Life (HRQOL) and Pain Response in Patients with Diabetic Peripheral Neuropathic Pain.
Johnson, F.R., S. Ozdemir, C.A. Mansfield, B. Sands, C. Siegel, S. Hass, D. Miller, and J. White. Weighing Treatment Benefits Against Treatment Risks: Crohn's Disease Patients' Willingness to Accept Risk-Benefit Tradeoffs.
Mladsi, D.M., and A.M. Barrett. Winners and Losers: Patterns in Economic Evaluations of Anti-Epileptic Drugs.
Johnson, F.R., S. Ozdemir, C.A. Mansfield, S. Hass, and J. White. Are Adults More Averse to Treatment Risks for Their Children Than They Are for Themselves?.
Earnshaw, S.R., M.R. Wilson, and A.V. Joshi. Budgetary Impact Analysis of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage: A US Health Plan Perspective.
Hauber, B., F.R. Johnson, and S. Ozdemir. Conjoint Analysis QALYs for Acute Conditions: An Application to Vasomotor Symptoms.
Javitt, J.C., S.E. Wolowacz, N.S. Roskell, F. Maciver, S. Kelly, A.M. Pleil, and G.P. Zlateva. Cost-Effectiveness of Pegaptanib in Age-Related Macular Degeneration: The Impact of Differences Between USA and UK Health Care Systems.
Wolowacz, S.E., N.S. Roskell, F. Maciver, and S. Kelly. Cost-Utility Analysis for Pegaptanib in Age-Related Macular Degeneration in the UK: The Impact of Demographic and Disease Characteristics.
Candrilli, S.D., K.L. Davis, A.V. Joshi, and B.J. Tortella. Healthcare Utilization and Costs Associated with Blunt and Penetrating Trauma in a United States Managed Care Population.
Zhou, X., C. Radigue, A.A. Allshouse, and A. Gilsenan. In Europe, How Representative are Overweight/Obese Subjects Recruited Via the Internet?.
Wolowacz, S.E.. The National Institute for Health and Clinical Excellence (NICE) Single Technology Appraisal (STA) Process: An Update on the First Round of Submissions.
Earnshaw, S.R., Y. Moride, A. Moshyk, and S. Rochon. Cost-effectiveness of Macugen Compared to Photodynamic Therapy (PDT) with Verteporfin and Standard Care in the Treatment of Subfoveal Wet Age-Related Macular Degeneration (AMD) in the Elderly in Canada.
Schnitzler, M.A., S.R. Earnshaw, C.N. Graham, W.D. Irish, and R. Sato. Lifetime Cost-Effectiveness of Calcineruin Inhibitor-Free Immunosuppressive Treatment After De Novo Renal Transplantation.
Williams, V., R. Morlock, S. Fehnel, M.M. Wills, C.D. Hill, S. Barrows, J. Cappelleri, and D. Feltner. Development and Evaluation of the Daily Assessment of Symptoms–Anxiety (DAS-A) Scale for Measurement of Onset of Symptom Relief in Patients with GAD.
Fehnel, S., L.D. Mcleod, H.M. Edin, and S.L. Hogue. Psychometric Evaluation of the Motivation and Energy Inventory –Short Form (MEI-SF).
Mcleod, L.D., S.E. Fehnel, M.M. Wills, L.R. Hamm, and K. Gilchrist. Psychometric Validation of a Patient-Reported Instrument Assessing Functional Status in Bipolar Disorder.
Britt, D.M., S.E. Fehnel, A.L. Granger, X. Zhou, and R. Williams. Quality of Life and the Prevalence of Vasomotor Symptoms in a Population-Based Sample of Peri- and Post-Menopausal Women.
Ettinger, B., A.J. Brogan, C.N. Graham, M.M. Amonkar, and R. Baran. Modeled cost impact of persistence with bisphosphonate therapy for women with postmenopausal osteoporosis.
Irish, W., J. Wang, B. Sherrill, K. Lentine, T. Burroughs, and M. Schnitzler. An Econometric Evaluation of All-Cause Graft Failure: A Population-Based Approach An Econometric Evaluation of All-Cause Graft Failure: A Population-Based Approach.
Earnshaw, S.R., A.J. Brogan, C.N. Graham, M.M. Amonkar, R. Baran, and A. Hebborn. The impact of persistency on economic models for bisphosphonate therapy in osteoporosis.
Johnson, F.R., S. Ozdemir, and B. Hauber. Is Relief Worth the Risk? Risk-Benefit Preferences for Treatments for Menopause Symptoms.
Johnson, F.R., S. Ozdemir, and A.B. Hauber. Stated or Misstated Health Preferences? Statistical Consequences of Suboptimal Experimental Design in Conjoint Surveys.
Earnshaw, S.R., P.A. Pankaj, S.D. Candrilli, J. DePlatchett, C.N. Graham, and L. Williams. 17th Annual Meeting & Showcase.
Gilsenan, A., P. Tennis, E.A. Andrews, X. Zhou, F. Coste, and C. Radigue. Is It Feasible to Conduct a Cohort Study via the Internet?.
Gilsenan, A.W., E.B. Andrews, A.N. Burdett, and R. Martin. Post-Marketing Safety Surveillance Studies Requiring Access to Patients and Charts: Does Persistence Yield Results?.
Burdett, A.N., C. Gard, A. Gilsenan, Z. Hirji, J. Raskin, and D. Miller. Prevalence and Costs Associated with Treating Depression with Painful Physical Symptoms in a Canadian Administrative Services Database.
Gilsenan, A., X. Zhou, P. Tennis, E.A. Andrews, F. Coste, and C. Radigue. Should We Believe Results Obtained from an Internet-Based Cohort Study?.
Candrilli, S.D., M.A. Lucero, K. Davis, H. Kan, and M. Covington. Burden of Illness Associated with Symptoms of Diabetic Peripheral Neuropathy and Diabetic Retinopathy.
Tafesse, E., A. Claxton, A.L. Granger, J. Sanders, D. Apelian, E. Atillasoy, and U. Iloeje. Estimates of Health Care Costs For Lamivudine-Refractory Chronic Hepatitis B (CHB) Patients.
Davis, K., S.D. Candrilli, H. Kan, M.A. Lucero, and M. Covington. Estimating the Effects of Diabetic Peripheral Neuropathy and Diabetic Retinopathy on Quality-of-Life Using Data from the 2001-2002 National Health and Nutrition Examination Survey.
Johnson, F.R., and S. Ozdemir. Bipolar Patients' Stated Therapy Preferences and Likely Adherence.
Johnson, F.R.. Conjoint Analysis: Application to Global Pricing and Reimbursement Strategy.
Earnshaw, S.R., J.C. Javitt, G.P. Zlateva, A.M. Pleil, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-Effectiveness Model for Age-Related Macular Degeneration: Comparing Early and Late Macugen® Treatment.
Earnshaw, S.R., J.C. Javitt, G.P. Zlateva, A.M. Pleil, C.N. Graham, A.J. Brogan, S. Shah, and A.P. Adamis. Cost-Effectiveness Model for Age-Related Macular Degeneration: Comparing Macugen® to Visudyne®.
Radigue, C., A. Wolf, A.A. Allshouse, and F. Coste. Costs and Healthcare Consumption in the Abdominally Obese Population.
Gregson, N.N., K.K. Sparrowhawk, and D.M. Mladsi. Global Pricing and Reimbursement Strategy: An Integrated Analytical Framework.
Earnshaw, S.R., J.C. Javitt, C.N. Graham, A.J. Brogan, G.P. Zlateva, S. Shah, and A.P. Adamis. Modeling Treatments for Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration: Cost-Effectiveness Methods.
Wolowacz, S.E., N.S. Roskell, A. Christie, G. Kerr, and D. Cameron. The cost of hospital care for relapsed breast cancer in the UK based on a large patient-level resource utilisation dataset..
Zhou, X., C. Radigue, F. Maneval, and F. Coste. Validity of Data Collected from an Internet-based Cohort Study.
Fehnel, S.E., L.D. Mcleod, H.M. Edin, and S.L. Hogue. Development and Preliminary Psychometric Evaluation of the Motivation and Energy Inventory – Short Form (MEI-SF).
Tennis, P., B.H. Sherrill, C. Fernandez, and E. Rodriguez. A Meta-Analysis of the Association Between Cancer Risk and Asthma.
Andrews, E.B., K.A. Hollis, D. Miller, P. Tennis, L. Bennett, V.Z. Ameen, A. Heath, D. McSorley, and S.F. Cook. A Patient Follow-up Survey Program for LOTRONEX (Alosetron HCL): Accessing Compliance with the Risk Management Program.
Miller, D., A.M. Walker, J. Avorn, J. Gurwitz, S.F. Cook, A. Feld, and P. Tennis. An Epidemiologic Program for the Study of the Safety and Utilization of LOTRONEX (Alosetron) in the U.S..
Burdett, A.N., C.C. Gard, C.J. Longo, J. Raskin, A. Gilsenan, J.S. Hopkins, and D.P. Miller. Prevalence and Costs of Difficult-to-Treat Depression in a Canadian Claims Database.
Eaton, S.C., E.B. Andrews, K.A. Hollis, J.S. Hopkins, V.Z. Ameen, L. Hamm, A.W. Mangel, R.L. Williams, and S.F. Cook. Prevalence and Demographics of IBS Respondents: Results from a Large Web-Based Survey.
Eaton, S.C., A.W. Mangel, K.A. Hollis, V.Z. Ameen, L.R. Hamm, E.B. Andrews, R.L. Williams, and S.F. Cook. Symptoms of Diarrhea-Predominant or Alternating IBS: An Exploratory Analysis.
Johnson, F.R., and E.B. Andrews. Using Stated-Preference Methods to Inform Pharmaceutical Risk Management.
Lucero, M.A., D. Mladsi, and J. Mauskopf. Communicating the Value: Developing Messages for Payers.
Alten, R.H., B. von Scheele, L. Gaffney, F. Maciver, and L. Niculescu. Cost-Effectiveness of Valdecoxib Compared to Diclofenac in Patients with Rheumatoid Arthiritis (RA) in the United Kingdom (UK) and Germany.
Earnshaw, S.R., S.M. Beard, L. Gaffney, A. Krishnan, and S.L. Hogue. The Impact of Premature Discontinuation of Antidepressant Therapy in Major Depressive Disorder in the UK.
von Scheele, B., K. David, L. Gaffney, L. Niculescu, and K.M. Verburg. The Total Cost of Treatment and the Cost-Effectiveness of Valdecoxib vs Diclofenac in the Treatment of Patients with Osteoarthritis (OA) of the Hip and/or Knee.
Williams, V.S.L., S.E. Fehnel, K.A. Hollis, and S.L. Hogue. Antidepressant-Induced Sexual Dysfunction (ADSD) in Europe: A Preliminary Investigation.
Irish, W., and B. Sherrill. Factors Associated with Chronic Allograft Nephropathy Following Renal Transplantation.
Irish, W., and B. Sherrill. Large-Scale Registry Analysis of the Relative Effect of Discharge Immunosuppression on the Rate of Chronic Allograft Nephropathy Using the Propensity Score Method.
Earnshaw, S.R., A. Krishnan, S.L. Hogue, and J.W. Williams. The Impact of Premature Discontinuation of Antidepressant Therapy in Major Depressive Disorder.
Johnson, F.R., R. Manjunath, and T.J. Hoerger. The Value to High-Risk Patients of Preventing a Case of Diabetes.
Eaton, S.C., S.F. Cook, E.B. Andrews, K.A. Hollis, V.Z. Ameen, A.W. Mangel, and S. Fehnel. Using a Web Panel to Aid Definition of a Target Population to Assist Risk Management.
Gilsenan, A., S. Pedrazzani, L. Bennett, L. Li, W. Yeager, and J.C. Haas. Observational Prevalence Study of HSV-2 (Genital Herpes) in Suburban Primary-Care Practices: Data Collection Procedures and Sampling Methods.
Hauber, A.B., and F.R. Johnson. Risking Health to Avoid Injections.
Mauskopf, J.A., C. Paramore, C.L. Won, and E.H. Snyder. Drug persistence patterns similar for rivastigmine-treated patients and donepezil-treated patients.
Beard, S.M., L. Gaffney, and L. Bamber. Economic Modelling of Antiplatelet Therapy in the Secondary Prevention of Stroke.
von Scheele, B., J. DePlatchett, L. Gaffney, B.M. Peña, and L. Niculescu. The Total Costs of Treatment with Valdecoxib Compared to Generic Diclofenac are Similar in Patients with Rheumatoid Arthritis in Germany.
Johnson, F.R., A.B. Hauber, and J.A. Mauskopf. Willingness to Pay, Willingness to Wait, and Super QALYS.
Rogers, S.M., H.G. Miller, B.H. Forsyth, T.K. Smith, and C.F. Turner. Audio-CASI: The Impact of Operational Characteristics on Data Quality.


text:
10 Stocks to Watch for Earnings
8. F5 Networks (FFIV) is a provider of networking, security and data storage software. It sells its products through a range of channels, including distributors, value-added resellers and systems integrators. The company is due to publish its fiscal 2012 first-quarter results on Jan. 18.
As per the consensus estimates of analysts polled by Bloomberg, the company is likely to report net income of $81.8 million on sales of $319.06 million, compared to net income of $72.2 on sales of $268.93 million recorded during the 2011 first quarter. F5 Networks is likely to report earnings per share of $1.01 during the quarter, compared to 88 cents in the year-ago quarter.
Gross margin is seen expanding to 82.59% from 81.79% earlier. Return on equity is seen increasing to 23.98% from 18.46%, while return on assets is estimated to expand to 18.63% from 13.58% in the prior year quarter.
Of the 35 analysts covering the stock, 71% recommend a buy, while the remaining suggest a hold. There are no sell ratings on the stock. Analysts polled by Bloomberg foresee the stock gaining an average 7.4% to $119.00 in the upcoming 12 months.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
Try it NOWJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
Try it NOWOnly $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
Try it NOWDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
Try it NOWJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOWAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
Try it NOWOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV

subset: commoncrawl


text:
* Sponsored Results
Write a Review
151 Maple St Cornish, ME 04020 zip code
Sign Up For The Rite Aid Automated Courtesy Refill Program.
Phone Website Map it
Wellness+ Members Earn Up To 20% Off Visit our website for more det...
200 Maple St Cornish, ME 04020 zip code
Phone Map it
We value your opinion. Please let us know what you think about us.
Print this free prescription drug coupon to use at your pharmacy
Wellness+ Members earn up to 20% off the entire store for a year.
Data provided by one or more of the following: SuperMedia, Acxiom, Infogroup


text:
US: Drinks Americas toasts Q2 spirits growth
By just-drinks.com editorial team | 7 October 2009
Drinks Americas has said that it expects net spirits sales in its second fiscal quarter to be significantly higher than last year.
Drinks Americas has so far received US$650,000 in spirits orders from distributors in its second fiscal quarter, which ends on 31 October, the group said today (7 October).
It expects to write the majority of this figure down as net revenue for the quarter, the firm said, giving it a strong increase on spirits sales of US$378,000 in the same quarter of last year.
"We are encouraged by the growth in our spirits lines of business," said company CEO Patrick Kenny.
Distributor demand has been particularly strong for Drinks America's Olifant vodka brand, which was boosted by a 22-city concert series fronted by rapper Snoop Dogg over the summer, the firm said.
Kenny added: "Our orders that we are producing now for spirits indicate that business is up 75% before we factor in Badass Beer, now selling in Michigan. We expect our inventory build on spirits and our expansion into the beer business to positively impact the coming quarters."
Badass Beer is the result of a partnership between Drinks Americas and rockstar Kid Rock.
Sectors: Beer & cider, Spirits
Companies: Drinks Americas
View next/previous articles
Currently reading -
US: Drinks Americas toasts Q2 spirits growth
7 Oct 2009 -


text: In our case (at two employers), we had long-standing relationships with G and Y, not related to being a content provider, e.g. major supplier of technology, major AdWords customer, major publisher, etc, so the content approach came to us, not the other way around. OTOH, if you are a future big brand but have good content now AND can see a gap in the current G offering, call Google's main number and ask to speak to the partnership manager for Google Maps (or whatever). Don't assume you will get rich (directly) from this relationship. ;)


text:
Quality CareFind out why Mayo Clinic is the right place for your health care. Make an appointment.
Meet the StaffFind a directory of doctors and departments at all Mayo Clinic campuses. Visit now.
Research and Clinical TrialsSee how Mayo Clinic research and clinical trials advance the science of medicine and improve patient care. Explore now.
Visit Our SchoolsEducators at Mayo Clinic train tomorrow's leaders to deliver compassionate, high-value, safe patient care. Choose a degree.
Professional ServicesExplore Mayo Clinic's many resources and see jobs available for medical professionals. Get updates.
Give to Mayo ClinicYou are an essential partner in our work to find answers for our patients. Donate now.
Subscribe to our Alzheimer's Caregiving e-newsletter to stay up to date on Alzheimer's topics.
Alzheimer's caregivers need all the support they can get. If you know someone who's caring for a loved one who has Alzheimer's disease, here's how to help.
When someone you care about is going through a difficult time, you might say, "Let me know how I can help." It's a nice gesture, but such offers can be difficult to accept — primarily because they're not specific. Instead, make concrete offers of help.
For example:
Sometimes sending a card or making a phone call to check in on a caregiver means a lot. Emails and text messages work, too — but often personal visits are even better. Contact with the outside world can help lift a caregiver's spirits.
Mayo Clinic is a not-for-profit organization. Proceeds from website advertising help support our mission. Mayo Clinic does not endorse non-Mayo products and services.
Advertising & Sponsorship
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic.


text:
But a friend's advice and the YWCA of Asheville may have saved his life, and he joins in the call for funds to save the nonprofit's Diabetes Wellness program, which may lose nearly half its funding if proposed state budget cuts go through.
After 10 months in the wellness program, which provides workout coaching, support groups and more, Robertson has lost about 42 pounds and says that now, when he looks in the mirror, he can say, "Welcome back." For a while there, he explains, he didn't recognize himself. A year ago, he was on three types of blood pressure medicine, and now takes just two. He's learned other ways to do things when it comes to diet too — like asking for a child's portion at a restaurant while offering to pay the adult price.
He laughs, acknowledging that he grew up on a traditional (and high-fat) Southern diet. "I can put away some groceries," says Robertson. But the YWCA's program and the encouragement to keep exercising have taught him a lot and likely saved his life.
But if proposed budget cuts to the state's Health and Wellness Fund go through, the YWCA program will lose almost half its support. At a June 2 press conference, YWCA-Asheville Director Holly Jones announced that she anticipates losing $100,000 in grant monies from North Carolina's Health and Wellness Fund. To make up the projected loss, Jones and Program Director Alfie Rodriguez have cut a full-time staff position and trimmed another to half-time. They've also cut some features of the program, such as a cooking class that helps participants learn healthier habits in their home kitchens.
"If this program is cut, a lot of people will suffer," says Robertson.
About 120 local residents currently participate, most of them minorities and most of them poor, YWCA Development Director Tami Ruckman adds. Type 2 diabetes is a national problem and a local one, disproportionately affecting African Americans and Latinos. More than 90 percent of the local Diabetes Wellness program, which partners with such local organizations as Mission Health System, are low-income, and about 65 percent are minorities, Ruckman mentions.
Part of the solution to keeping them in the program, despite the state cut? A private donor has offered to donate $100 for every new member to Club W — the nonprofit's fitness center. Club W memberships fund most of the programs the YWCA offers, Jones explains, remarking, "We're not going to let this program go down without a fight," says Jones. "We've figured out ways [to cut costs] but we still need $25,000 by June 30."
Rodriguez and Jones both emphasize that the YWCA program works. One participant was on dialysis and on the list for a kidney transplant when he started. After five months of exercising and losing weight and, he's healthy enough to be off dialysis and off the transplant list.
"How many of us have started an exercise program and not finished? We have a 78 percent success rate," says Jones, who's also a Buncombe County commissioner and works with the childhood-obesity project spearheaded by first lady Michelle Obama. The YWCA's Diabetes Wellness program has been profiled statewide as one of the most effective in addressing health disparities related to race and managing the disease.
Robertson has his own way of touting the program. He'd been a member of the YWCA for three years before he got serious, rarely coming more than one or two times a month, much less starting a program that would really improve his health.
But a friend convinced him that at the YWCA, it didn't matter how big he'd gotten, what he looked like ("I couldn't even wear tie-up tennis shoes," Robertson recalls) or whether he got around on a cane or a walker. The day he arrived to get started, an elderly woman on a cane walked in, and inside, there were folks just like him, trying to turn their health around. And there was always someone available to help.
His friend said, "See? They don't care. It's the Y-Dub-Ya!"
For more information about the program, or to make a donation, visit ywcaofasheville.org or call 252-7206.
Read more articles in:
NewsSubscribe to XpressMail. Free Sneak Peek. Every Week.
Want to know what's coming out in Xpress this week before the paper even hits the stands?
We've got your free sneak peek, along with deals available in XpressMail, our weekly email newsletter. (It's the best we can do without time travel.)
Related Articles
No commments yet.
Make a comment


text:
David O. Selznick was a major Hollywood mogul, producing great films such as Gone with the Wind and Spellbound. But he was also a workaholic micromanager, obsessed with sending office memos. Through his memos, Selznick dictated every detail of production at his movie studio, from the size of Rhett Butler's collars to Alfred Hitchcock's camera angles. Produced by Eric Molinsky.
Eric MolinskyLeave a Comment
Register for your own account so you can vote on comments, save your favorites, and more.
Learn more.
Please stay on topic, be civil, and be brief.
Email addresses are never displayed, but they are required to confirm
your comments. Names are displayed with all comments. We reserve the
right to edit any comments posted on this site. Please read the
Comment Guidelines before
By leaving a comment, you agree to New York Public Radio's
Privacy Policy and
Terms Of Use.


text:
Booklyn our love is always hungry at
almost 16 pounds its no wonder, and
this is just an example of what she always
wants. No matter whose food or drink it is. She prefers ice water with big chunks of ice. Hey like any woman she knows what she likes.
She's a BIG girl
This story is inappropriate and should be flagged for moderation. Please choose from one of the following options:


text:
Joseph Abboud
Born and raised in a working-class Boston household, Joseph Abboud got his start in the fashion industry at age 16 when he landed a part-time job at the influential retailer Louis Boston. After honing his skills there and at Ralph Lauren, Abboud launched his own eponymous label in 1987 — specializing in tailored men's clothing and sportswear marked by clean, classic lines and brown and olive tones. Before long Abboud became a key player in the American menswear scene, crafting smart suits and tuxedos for celebrities and regular guys alike. Abboud stepped down from leading his company in 2005, but with Bernardo Rojo at the helm, the label continues to create fine clothing with the same vigor that originally propelled it to prominence. From leather wallets and lace-up shoes to cotton dress shirts, durable luggage, and versatile wool coats, every item is made in the U.S.
New Joseph Abboud Sales
Final Few
Sportcoats & Dress Pants
Past Sales Featuring Joseph Abboud
SALE ENDED ON: March 10, 2014
SALE ENDED ON: March 7, 2014
Dress Shoes Feat. Mezlan
With offerings from old masters and modern mainstays, this selection of dress shoes has everything the discerning gentleman could want. Be it monkstraps, oxfords, loafers, and more — in rich calfskin or suede — this is the footwear to take your look to the next level.
SALE ENDED ON: March 4, 2014
Sunday Night Steals
End the weekend on a high note with a great deal on pieces from some of your favorite designers, including 7 for All Mankind, John Varvatos, and Gant, among others. You'll find everything here from watches and shades to sportcoats and cufflinks. It's the kind of selection you'll want to tell your friends about — but only after you've made your picks.
SALE ENDED ON: March 1, 2014
Suit Separates up to 70% Off
Sometimes the situation calls for a suit and sometimes it doesn't. This sale helps with those in-between times, with a host of elegant sportcoats and trousers from some of the top names in menswear — Joseph Abboud, John Varvatos, Corneliani, and more.
SALE ENDED ON: February 22, 2014


text:
Blatter: Goal-line tech a necessity
FIFA president Sepp Blatter declared goal-line technology "a necessity" after Ukraine became the latest victims of its absence from the game.
The European Championship co-hosts were denied an equaliser in Tuesday night's decisive 1-0 Group D defeat to England when officials failed to spot Marco Devic's shot had crossed the line.
Blatter, who hopes to convince the game's rule-makers - the International Football Association Board - to give technology the green light, posted on Twitter: "After last night's match #GLT is no longer an alternative but a necessity."
Blatter became a convert to goal-line technology after Frank Lampard was denied a legitimate goal in England's 2010 World Cup defeat to Germany.
That failed to convince UEFA president Michel Platini - the favourite to succeed Blatter as the most powerful man in world football - who remained wedded to his belief additional assistant referees behind each goal was the best way forward.
Yet, lasTuesday night's referee, assistant referee and AAR all failed to spot Devic's shot had narrowly crossed the line before John Terry's acrobatic clearance prevent it hitting the back of the net.
That left Platini red-faced after he made bold claims on the eve of the game about the effectiveness of five officials.
He told reporters in Warsaw: "With five, officials see everything.
"They don't take decisions without being fully aware.
"There's also a uniformity of refereeing. For example, they don't call unintentional handballs. That uniformity has led to more flowing football."
Platini also attempted to justify his opposition to goal-line technology.
"Goal-line technology isn't a problem," he said.
"The problem is the arrival of technology because, after, you'll need technology for deciding handballs and then for offside decisions and so on. It'll be like that forever and ever.
"It'll never stop. That's the problem I have."
However, the introduction of some form of goal-line technology into football is now virtually inevitable.
However, the introduction of some form of goal-line technology into football is now virtually inevitable.
IFAB are expected to approve at least one of two systems that have been subject to in-depth testing when they meet in Zurich on July 5.
Hawk-Eye, the camera-based system made famous after being successfully introduced to tennis, and GoalRef, which relies on a chip in the ball, were both selected for further tests at IFAB's meeting in March.
One of them could be introduced for the first time at December's FIFA Club World Cup in Japan.
England's friendly win against Belgium at Wembley this month witnessed a Hawk-Eye test, although the results were not made public.


text:
President Obama's schedule for Sunday, March 9
President Obama challenges students to file financial aid form
President Obama misspells "respect" during Aretha Franklin tribute
President Obama's schedule for Friday, March 7
Ukrainian Euromaidan volunteer receives State Department's International Women of Courage Award
Video shows Obama and Biden working out at White House
President Obama and VP Biden keeping America spry
Michelle Obama to appear on 'Parks and Recreation'
Michelle Obama books 'Parks and Rec' cameo
Michelle Obama, FDA propose changes to Nutrition Facts food label
First Lady Michelle Obama raps about healthy wraps
Michelle Obama visits 'The Tonight Show' in New York
Eleanor Roosevelt ranked best first lady
Barack Obama, Michelle exchange sweet Valentine's Day tweets
Hollande, Obama toast at White House state dinner after long day
Michelle LaVaughn Robinson Obama (born January 17, 1964) is the wife of the 44th and incumbent President of the United States, Barack Obama, and is the first African-American First Lady of the United States. Raised on the South Side of Chicago, Obama attended Princeton University and Harvard Law School before returning to Chicago and to work at the law firm Sidley Austin, where she met her future husband. Subsequently, she worked as part of the staff of Chicago mayor Richard M. Daley, and for the University of Chicago Medical Center. In 2011 Forbes Magazine named Michelle Obama the most powerful woman in the world in Forbes Magazine's List of The World's 100 Most Powerful Women
Throughout 2007 and 2008, she helped campaign for her husband's presidential bid and delivered a keynote address at the 2008 Democratic National Convention. She is the mother of two daughters, Malia and Sasha, and is the sister of Craig Robinson, men's basketball coach at Oregon State University. As the wife of a Senator, and later the First Lady, she has become a fashion icon and role model for women, and an advocate for poverty awareness and healthy eating.
Michelle LaVaughn Robinson was born on January 17, 1964, in Chicago, Illinois, to Fraser Robinson III, a city water plant employee and Democratic precinct captain, and Marian (née Shields), a secretary at Spiegel's catalog store. Her mother was a full-time homemaker until Michelle entered high school. The Robinson and Shields families can trace their roots to pre-Civil War African Americans in the American South. Specifically, her roots can be traced to the Gullah people from South Carolina's Lowcountry region. Her paternal great-great grandfather, Jim Robinson, was an American slave in the state of South Carolina, where some of her paternal family still reside. Her maternal great-great-great grandmother, Melvinia Shields, also a slave, became pregnant by a white man. His name and the nature of their union have been lost. She gave birth to Michelle's biracial maternal great-great grandfather, Dolphus T. Shields.


text:
YouTube Capture has been updated to add support for the iPad. Now universal, YouTube Capture allows you to take videos and directly upload them to YouTube. Just like the iPhone version, YouTube Capture on the iPad is capable of uploading videos at 1080p.
While this won't have as much utility as the iPhone version, it's good that Google is trying to accommodate multiple use cases. Hopefully, Google Maps will be the next Google app to get the iPad treatment.
Do you take video with your iPad? Is the arrival of YouTube Capture for iPad good news? Let us know!
I hope this app forces people to start recording videos in the horizontal. I can't stand vertical video syndrome. Here's a funny PSA for those who need a refresher: http://www.youtube.com/watch?v=Bt9zSfinwFA
I don't really find myself taking video with the iPad. This update however might be worth giving it a try.
I just got an iPad Mini for free... well through my points for flying so much. Ironically I'm going up north ice fishing this weekend. I usually take a few videos as well as pictures but never thought of using the iPad for that. Perhaps I'll have to take it along with me and give that a try.
I do not find the need to take a picture with an iPad because it is so damn big; I would rather use my phone; however, the new iPad Mini is rather small, it might be okay to take pictures with it. I'm looking for more and more support for applications.
The quality of the video won't be as good on the iPad... And taking a video with an iPad in public is kinda embarrassing.
for people who make videos on youtube this is good but i don't see the benefit would be for the average user


text:
You have movies, pictures, games and more, but they are all stuck on your computer back home! Bring your files with you with the 8GB DataTraveler portable usb drive! The stylish black drive will look great anywhere, and is an convenient way to transport your data that wont put a hurting on your wallet. It's capless design means you have one less thing to lose as the USB connector is safely housed inside the case.
But wait - There is more! Today, you get 2 drives! Keep one with your laptop and carry one with your keys. Trade them with your friends to share photos and documents. Never leave your data at home again.
Features Include:
Package Includes:


text: Taylor Swift Bikini Poll June 22, 2010 5:00 AM View Comments Related Tags: bahamas, bikini Wearing her high-waisted 1950′s two-piece polka dot bikini, country sensation [lastfm]Taylor Swift[/lastfm] attempted to tan her ivory skin on the beach in the Bahamas this weekend. The 20-year-old is very mature for her age. Take Our Poll View Comments


text:
Abd al Rahman Abdullah Ali MuhammadAbd al Rahman Abdullah Ali Muhammad is a 31- or 32-year-old citizen of Yemen. As of January 2010, the Guantánamo Review Task Force had recommended him for transfer. As of March 12, 2014, he has been held at Guantánamo for 12 years one months. |
Internment Serial Number:


text:
August 8th, 2011
Recipe For Disaster
Let's see here: (1) preggos (2) belly-paint (3) chihuahua (4) Bud Light…it's like Paris Hilton meets a tailgate party for a Jeff Foxworthy show.
Recipe For Disaster, -
When I first clicked onto this photo, I thought that she had a really big open wound. YUK. Then I noticed that it was some sort of head-like a bear's??? YUK, YUK, YUK. Why? I know that people get tattoos that mean something to them. Have to wonder what this means to her. She should have saved that money for something else, or put it into a savings account. Just my opinion….
It is really nice of Walmart to provide electric scoooters for the convenience of their shoppers. No pregnant woman should have to carry a 24 pack AND a Chihuahua across a big store like Walmart. It would be even nicer if Walmart had a service that delivered the beer and Chihuahua's to her doorstep.
@ Toeachhisown-I am glad that you are still hanging on, but I think that you have it backwards-I thought that the Devil liked idle hands-Lol-but I guess it depends on what you're doing. Hopefully, whatever you are doing brings you joy and prosperity. PS. I already posted a message for you, but somehow it never posted.
Well, 2348578 people already mentioned that the beer isn't hers, so there's that. Then, there's the fact that no one on here has ANY clue why she's in the scooter. I had to use a scooter when I went out while was pregnant due to blood pressure, and it's a-holes like some of these people that made me almost never leave the house.
Okay, first off the beer is not hers. She is in a scooter because she's 9 months pregnant and had her baby two weeks later. Her moms an artist and painted on her stomach a monkey to be cute. This is at like midnight which is was the man, who is not her baby daddy but her brother is wearing pajamas. You guys are sick as heck and have no life.


text:
Wednesday Mar 5 | Denver Stiffs
Q&A with Mavs Moneyball's Rebecca Lawson: Monta Ellis right complement for Dirk Nowitzki
The Nuggets are about to face the 36-25 Dallas Mavericks. Dirk Nowitzki is leading his team on a playoff run and has been joined this season by an unlikely partner in Monta Ellis.
Trending on the Topix Network
Dallas Mavericks are the Team No Playoff Team Wants To See
As the calendar turns from February to March, and the All-Star break is firmly in the rear view, the potential NBA playoffs are beginning to take shape.
Talking Knicks with Posting and Toasting
Seth Rosenthal from Posting and Toasting was kind enough to answer some questions about the Knicks before they host the Mavericks tonight.
The Knicks did not make any deadline trades
Some things were close to happening, but didn't. After a couple teams had expressed interest in the trade-requestin' Beno Udrih , it sounded like he might head to Denver in exchange for Jordan Hamilton.
Nowitzki, Mavericks return with eye on playoffs
Former NBA player Avery Johnson, left speaks with West Team's Dirk Nowitzki, of the Dallas Mavericks before the NBA All Star basketball game, Sunday, Feb. 16, 2014, in New Orleans.
Breaking down the Dallas Mavericks' Mount Rushmore candidates
There's a lot of very important figures throughout Dallas Mavericks history, but which four most deserve to be honored on a Mavericks' "Mount Rushmore."